Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases

Martínez-Hernández, María I.; Acosta-Saavedra, Leonor C.; Hernández-Kelly, Luisa C.; Loaeza-Loaeza, Jaqueline; Ortega, Arturo

doi:https://doi.org/10.1155/2023/7389508

BioMed Research International

On this page

Abstract Introduction Conclusion Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2023 | Article ID 7389508 | https://doi.org/10.1155/2023/7389508

Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases

María I. Martínez-Hernández,¹Leonor C. Acosta-Saavedra,¹Luisa C. Hernández-Kelly,¹Jaqueline Loaeza-Loaeza,¹and Arturo Ortega¹

Academic Editor: Anna Chiarini

Received10 Nov 2022

Revised18 Jan 2023

Accepted23 Jan 2023

Published31 Jan 2023

Abstract

Neurodegenerative processes encompass a large variety of diseases with different pathological patterns and clinical features, such as Alzheimer’s and Parkinson’s diseases. Exposure to metals has been hypothesized to increase oxidative stress in brain cells leading to cell death and neurodegeneration. Neurotoxicity of metals has been demonstrated by several in vitro and in vivo experimental studies, and most probably, each metal has its specific pathway to trigger cell death. As a result, exposure to essential metals, such as manganese, iron, copper, zinc, and cobalt, and nonessential metals, including lead, aluminum, and cadmium, perturbs metal homeostasis at the cellular and organism levels leading to neurodegeneration. In this contribution, a comprehensive review of the molecular mechanisms by which metals affect microglia physiology and signaling properties is presented. Furthermore, studies that validate the disruption of microglia activation pathways as an essential mechanism of metal toxicity that can contribute to neurodegenerative disease are also presented and discussed.

1. Introduction

Microglial cells are present in the central nervous system (CNS) within the brain parenchyma. Microglia are considered the brain “macrophages” since these cells are involved in multiple functions from the embryonic stage to adulthood, such as immune vigilance, synaptic pruning, neurogenesis, and cleansing; they also act as sensors of environmental molecules, such as ions, neurotransmitters, cytokines, chemokines, and growth factors [1–3].

Microglia are dynamic and heterogenous, and these cells can activate and change their phenotype depending on the brain microenvironment. The cells of this lineage can polarize to an “M1” or “M2” phenotype; the first one is characterized by the secretion of proinflammatory molecules such as tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 23 (IL-23), nitric oxide (NO), and reactive oxygen species (ROS), while the latter phenotype secretes anti-inflammatory molecules such as interleukin 4 (IL-4), interleukin 10 (IL-10), interleukin 13 (IL-13), and arginase 1 (Arg-1) [1, 3–5]. MicroRNAs (miRNAs) play a crucial role in CNS diseases through posttranscriptional regulation. In this sense, miRNAs are essential regulators mediating microglial activation and polarization [6].

In the brain, metals play an essential role in health and disease. Metals are natural components of the earth crust disseminated to the biosphere through human activities [7, 8]. Some metals are physiologically essential, for example, cobalt (Co), chromium (Cr), copper (Cu), iron (Fe), manganese (Mn), molybdenum (Mo), nickel (Ni), selenium (Se), and zinc (Zn) among others, but can be toxic in large quantities or certain forms [9, 10]. Metals are usually essential components in biological molecules and involve multiple enzymatic reactions [11]. The difference between the deficit, physiological, and toxic metal concentrations are relatively small; therefore, it is important to have strict control of their concentrations. It is also pertinent to mention that small amounts of nonessential metals such as aluminum (Al), cadmium (Cd), mercury (Hg), and lead (Pb) can also promote severe damage since these metals disrupt the physiological activity of the essential metals [9, 10].

Neurodegeneration is thought to be the most common manifestation of metal toxicity. A link has been found between abnormal brain metal accumulation and various neurological disorders, such as Alzheimer’s (AD) and Parkinson’s (PD) diseases [12–14].

Environmental exposure to metals or dysregulation of this essential metals homeostasis contributes to microglial activation and, in turn, can trigger an inflammatory response, which depends on factors such as prolonged induction of cytokines, receptor activation, dysregulation of signaling pathways, or even the absence of sufficient anti-inflammatory mediators to reduce the response. This neuroinflammation can coincide with other mechanisms of neurotoxicity and cause alteration of the synaptic activity or neuronal death [12–15].

The present contribution is an approach to analyze our current understanding of the role that microglial activation plays under exposure to both essential and nonessential metals and how these processes contribute to the development of neurodegenerative diseases.

2. Microglia Cells

Microglia cells are among the most versatile cells in the brain, as these cells are involved in various critical actions for the development and homeostasis of the brain. Microglia represent 10%–15% of the nonneuronal cells in the brain and are generally known as resident immune cells that closely resemble peripheral macrophages [16]. These cells respond rapidly to stimuli, secrete a great diversity of signaling molecules, and, interestingly, can also change their phenotype.

Microglia play a key role in the shaping and fine-tuning of brain circuits in a healthy brain. Together, microglia and plasma membrane receptors respond to the internal and external cellular microenvironment, playing an essential role in CNS physiology and pathology [17]. Microglia express various plasma membrane and cytoplasmatic receptors (Figure 1), enabling them to participate in CNS physiology and pathology, as these cells respond immediately to the internal and external cellular microenvironment. Among these microglia receptors are the pattern recognition receptors (PRRs) that detect pathogens associated with molecular patterns (PAMPs), molecular patterns associated with tissue damage (DAMP), and neurotransmitter receptors (Figure 1).

Figure 1

Receptor repertoire in microglial cells. Microglia cells express several families of receptors. ApoER2 belongs to the low-density lipoprotein receptors and is known to bind to and internalize apoE-containing lipoproteins. Tyro3 is an RTK involved in microglial activation. CD36 is a representative type C receptor with scavenger function involved in Aβ clearance. The stimulation of P2X7R, a purinergic receptor, can increase cytoplasmic calcium levels and the enhanced superoxide anion. A2a is an adenosine receptor that induces expression of NGF, COX-2 mRNA, and synthesis of PGE2. TLR4 is a member of the pattern recognition receptors family and was shown to be essential for microglia to induce proinflammatory cytokine release and ROS production; CD47 participates in the phagocytic functions of microglia. Nod-like receptors (NRL) are a family that regulates inflammation, cell death, proliferation, and transcriptional reprogramming of immune genes. CD11B is a β-integrin receptor, and its expression corresponds to the severity of microglial activation. mGluR is a metabotropic receptor, and its activation induces neurotoxic microglial phenotype and TNF-α release; NMDAR activation in microglia leads to NO release in response to NF-κB signaling. AMPAR modulates TNF-α release.

The PRRs include Toll-like receptors (TLRs) such as TLR4 and TLR1/2 [18, 19]. Signaling through TLRs activates downstream signaling cascades through two major adapter proteins, myeloid differentiation primary-response protein 88 (MyD88), and domain-containing adaptor interferon-β (TRIF) that converge at the IkB kinase (IKKs) and the mitogen-activating kinases (MAPKs), leading to the activation of transcription factors, particularly nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1), to promote the expression of proinflammatory mediators [20].

The NOD-like receptors (NLRs) are cytosolic sensors containing NACHT and C-terminal leucine-rich repeat (LRR) domains. Upon activation by different stimuli, such as PAMPs or endogenous danger signals, the NLRP3 inflammasome is formed after the association of NLRP3 with the adaptor protein apoptosis-associated speck-like protein containing CARD, also known as PYCARD (ASC) and procaspase-1 [18, 21]. It has been shown that NLRP3 is expressed in microglia cells but not in astrocytes and that the stimulation with amyloid-β peptides activates NLRP3 and IL-1β secretion [22].

The type C receptors (CLRs), like the receptor encoding C-type lectin domain family 7 member A (CLEC7A), are involved in autophagy and phagocytosis processes, and amoeboid microglia are characterized by their high CLEC7A expression [23, 24]. Microglia also express receptors that help to endocytose apoptotic cells, aggregated proteins, and lipoprotein particles. These receptors include scavenger classes such as cluster of differentiation 36 (CD36) or Platelet glycoprotein 4 and macrophage receptors with collagenous structure (MARCO). It has been found that CD36 is expressed in human fetal microglia, N9-immortalized mouse microglia, and the brain of AD patients [25, 26]. MARCO is responsible for the microglia actin cytoskeleton rearrangements, characterized by the fact that these cells appear round and are slightly adherent [27].

Low-density lipoprotein receptors (LDLRs) are also expressed in microglia. Apolipoprotein E (ApoE) is known to bind to microglial LDLR to become internalized via receptor-mediated endocytosis and regulate c-Jun N-terminal kinase (JNK) activation [28]. Three tyrosine kinase receptors (RTK), Tyro 3 protein tyrosine kinase (Tyro3), Axl receptor tyrosine kinase (Axl), and MER protooncogene tyrosine kinase (Mertk) that regulate the innate immune response in dendritic cells and macrophages, mediate the engulfment of apoptotic cells by phagocytes that have been described in microglia [29, 30]. Mertk and Axl expression is prominently upregulated in the inflammatory environment and upon a cuprizone (Oxalic acid bis (cyclohexylidene hydrazide)) challenge [31–33].

Microglia cells express chemokine receptors, like the C-X3-C motif chemokine receptor 1 (CX3CR1) and the C-X4-C motif chemokine receptor 4 (CXCR4). CX3CR1 has a prominent microglia expression; it is a G-protein-coupled receptor and transduces several well-characterized signaling pathways leading to the activation of transcription factors, including NF-κB and cAMP responsive element binding protein (CREB) [34, 35]. CXCR4 receptors mediate IL-6 upregulation via ERK, PI3k/Akt, and NF-κB signaling pathways [36].

Other receptors expressed in microglia are integrin-like receptors, such as integrin subunit alpha M (CD11b) and integrin subunit alpha X (CD11c). Microglial activation is represented by an increased expression of CD11b and CD11c, and NO plays a crucial role in its expression [37, 38].

Purinergic receptors, such as P2Y12 (P2Y12R) and P2X7 (P2X7R) receptors, have also been reported in microglia. The P2Y12R is active in these cells under basal conditions, albeit negatively regulated after activation; it drives migration and phagocytosis [39], while P2X7R reduces microglial phagocytic capacity and produces mature caspase-1 by activating the inflammasome [40].

Adenosine receptors, such as A2a, promote the secretion of inflammation mediators and phagocytosis. Activation of microglial A2a receptors also induces the expression of cyclooxygenase 2 (COX2) mRNA, the synthesis of prostaglandin E2 (PGE2), and the potentiation of NO release from activated microglia [41].

Furthermore, microglia express immune receptors that regulate the amplitude and duration of their activation. These include the superfamily of immunoglobulin (Ig-SF) molecules that deliver stimulatory or inhibitory signals through both protein tyrosine kinase and protein tyrosine phosphatase pathways. Among the most studied of these molecules, it is pertinent to mention triggering receptor expressed on myeloid cells (TREM), an activating receptor that binds to phospholipids [42]. Expression of TREM2 is abundant in all forebrain regions. It is involved in homeostatic microglial function [43]. The sialic acid binding immunoglobulin-like lectin 3 (CD33) binds to sialic acid and triggers inhibitory signals in human microglia [44]. Low CD33 levels have been reported in newborn and adult mice; interestingly, microglial polarization with granulocyte macrophage colony-stimulating factor (GM-CSF) followed by interferon gamma (IFN-γ) and Lipopolysaccharide (LPS) has also been found [45].

CD200 is a transmembrane glycoprotein, mainly expressed in neurons that binds to its specific receptor (CD200R), expressed exclusively in microglia and macrophages [46]. The interaction CD200/CD200R maintains microglia in a quiescent state; therefore, CD200/CD200R signaling disruption can cause microglial over reactivity [47].

Interestingly, signal regulatory protein α (SIPRα; also known as SHPS-1, p84, and BIT) is a membrane protein that binds to CD47, activating the protein tyrosine phosphatases SHP-1 or SHP-2 through their cytoplasmic region [48, 49]. SIPRα downregulation triggers an inflammatory response in microglia, revealing an inhibitory effect of SIPRα in microglial activation [50].

2.1. Receptors for Neurotransmitters and Neuropeptides

Microglia also express multiple neurotransmitters and neuropeptide receptors involved in glial-neuronal interactions (see Figure 1) [51, 52]. These receptors allow microglia to monitor neuronal activity, supporting microglial involvement in synaptic plasticity modulation and the subsequent change in the dendritic tree density. Neurotransmitter receptors are of utmost importance since these proteins detect and eliminate damaged neurons and promote the secretion of neurotrophic factors needed for neuronal regeneration. These receptors regulate the release of inflammatory cytokines in response to several stimuli. Microglia express ionotropic and metabotropic glutamate receptors (GRI, GRM). The former are α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA, GRIA), N-methyl-D-aspartate (NMDA, GRIN), and kainate (KA, GRIK) receptors [53]. Metabotropic glutamate receptors are classified according to their receptor-coupled second messenger system and their specificity for different agonists into three groups; group I includes mGluR1/5 (GRM1/5), group II includes mGluR2/3 (GRM2/3), and group III has mGluR6/8 (GRM6/8) [53].

In line with these findings, a study by Noda demonstrated that the expression of functional GRIA receptors in rat microglia might mediate neuron/microglia communication in the physiological and pathological states [54]. A study by Hagino et al. showed that the potentiation of microglial GRIA receptors serves as a negative feedback mechanism for regulating TNF-α release [55]. Interestingly, Fontain et al. has demonstrated an endogenous ionotropic glutamatergic transmission mediated mainly through GRIA and GRIK receptors and, to a smaller extent, by GRIN receptors, positively regulating the microglial dendritic structure and process dynamism [56]. Accordingly, Liu et al. showed that microglia exposed to glutamate increase their migration, and this chemotaxis is mediated by GRIA and GRM receptors [57].

There is also evidence supporting the microglial expression of GRIN receptors. For example, microglia are transiently activated following injections of NMDA into the cortex, and these receptors may enhance the release of TNF-α, IL-1, and NO [58, 59]. The stimulation of microglial GRM3 receptors prevents mitochondrial stress and apoptosis [60]. Furthermore, Taylor et al. demonstrated that stimulation of GRM2 induces TNF-α release, which contributes to microglial neurotoxicity via neuronal TNF receptor 1 and caspase-3 activation [61]. Byrnes et al. demonstrated that GRM5 receptor stimulation inhibits microglial activation in vitro, proliferation, NO, TNF-α, and ROS production [62]. More recently, Zhang et al. reported that activation of GRM5 inhibits inflammatory signaling triggered by alpha-synuclein (α-Syn); GRM5-mediated signaling partially inhibited microglia activation [63].

GABA is the major inhibitory neurotransmitter in the CNS, maintaining the healthy balance between excitation and inhibition in the brain, whose imbalance is significantly affected in epilepsy, AD, autism spectrum, and schizophrenia [64–66].

Gamma-aminobutyric acid (GABA) receptors are expressed in microglia. It was demonstrated that activation of GABA_B receptors attenuates the LPS-induced IL-6 and interleukin 12p40 (IL-12p40) release [67]. Moreover, the expression of dopamine receptors (DR) such as D1R, D2R, D3R, D4R, and D5R in microglia has been documented. Also, it was observed that in a damaged brain, the expression of D2R is present in ionized calcium-binding adapter molecule 1 (Iba-1) immunoreactive inflammatory cells (microglia) [68].

Microglia express and respond to the muscarinic acetylcholine receptor (mAChRs) agonists. In this context, it has been observed that carbachol increases the chemotaxis activity and decreases the phagocytic activity of cultured microglia [69]. Besides, receptors for neuropeptides, such as the neurokinin-1 receptor (NK1R), are necessary for substance P- (SP-) mediated chemotaxis [70]. In this sense, the activation of bradykinin receptors, specifically the B2 and B1 receptors, amplifies inflammation mediators (TNF-α and NO synthesis) [52, 71]. The receptors described above are of utmost importance since their activation in microglia determines the balance between a proinflammatory or anti-inflammatory phenotype.

3. Microglial Activation: M1 and M2 Phenotypes

Microglia activation or polarization is often classified as classical (M1) or alternative (M2) [72], following the paradigm of macrophages [73]. In Figure 2, both microglial phenotypes are represented. M1 activation is characterized by the simultaneous activation of TLR and IFN-γ signaling pathway and the production of proinflammatory cytokines and chemokines, such as TNF-α, IL-6, IL-12, and C-C motif chemokine ligand 2 (CCL2). Moreover, NADPH oxidase generates superoxide anion and ROS, as well as inducible nitric oxidase synthase (iNOS), which converts L-arginine to NO. Another inflammatory mediator produced by M1 is matrix metalloproteinase 12 (MMP12). M1 microglia also express high amounts of major type II histocompatibility complex (MHC type II), costimulatory molecules, Fc receptors, and integrins [74].

Figure 2

Microglial activation, either M1 or M2, can be triggered by intrinsic or extrinsic stimuli. Stimuli can be signals of neuronal damage, neurotransmitter release, altered ion, and metal concentrations. Microglial M1 activation increases immune stimulation, blocks axonal remodeling, and neurogenesis and triggers neuroinflammation, a phenomenon characteristic of neurodegenerative diseases, by releasing inflammatory cytokines that disrupt the neuronal network. M2 microglial activation is distinguished from M1 by neuroprotection and neuronal regeneration and tissue remodeling functions and by its releasing factors like arginase-1, IL-10, IL-4, IL-13, CD206, and TGF-β.

Microglia M2 secretes growth factors such as IGF-I, fibroblast growth factor (FGF), and colony-stimulating factor 1 (CSF1), as well as neurotrophic factors like nerve growth factor (NGF), neurotrophic factor derived from the brain (BDNF), neurotrophins (NTs), and glial cell derived neurotrophic factor (GDNF). M2 activation leads to anti-inflammatory, healing, and repair activities of microglia. IL-4 can induce IL-13 and IL-10 release as well as activation of the receptor activated by the gamma peroxisome proliferator (PPARγ), liver receptor X (LXR), and retinoic acid receptor (RXR), respectively [18]. Likewise, M2 activation promotes the release of anti-inflammatory cytokines, such as IL-10 and TGF-β, and induces Arg-1, which supports the conversion of arginine to polyamines (Figure 2). Neurotrophic factors activate tyrosine kinase receptors (RTK), which regulate synaptic strength and plasticity [4, 75].

The polarization toward M1 or M2 microglial phenotype is also regulated by miRNAs, which are molecules of 18–25 nucleotides long that regulate gene expression at the posttranscriptional level [76]. miRNAs activate microglia during inflammation [77]. The group of proinflammatory miRNAs, such as miRNA-155, is induced by LPS [78]. miRNA-155 promotes apoptosis and increases the release of proinflammatory cytokines. Another miRNA involved in the inflammatory response is miRNA-125, which is induced by TLR agonists and modulates the classical NF-κB inflammatory pathway [79]. Another study identified that miRNA-101 regulates proinflammatory cytokine expression, increasing the production of IL-6 and TNF-α and inhibiting MAPK phosphatase-1 (MKP-1) [80].

Other miRNAs are also involved in inflammation. For example, miRNA-146 is expressed at the highest microglia levels and upregulated in all lesion types [81]. In this sense, it has been reported that during microglia activation, miRNA-21 downregulation increases the production of the Fas ligand (FasL), which mediates neurotoxicity in rat microglia [82].

It has also been observed that microglia cultured with GM-CSF and IFN-γ downregulate miRNA-124; these cells show an activated phenotype with a low level of miRNA-124 expression [83]. This miRNA has been considered anti-inflammatory, a two-day with miRNA-124 after an ischemic insult increases of Iba-1+ cells expressing the M2 marker CD206 and a parallel pronounced decrease of the M1 marker CD16/32; these data confirm the protective role of miRNA-124 [84].

Another miRNA expressed during the microglial activation process is miRNA-204. A study by Li et al. found that miRNA-204 inhibits the expression of Sirtuin1 (SIRT; a NAD+-dependent class III histone deacetylase) and upregulates the expression of matrix metallopeptidase 9 (MMP9), iNOS, and IL-1β [85]. In another study by Yao et al., it was demonstrated that miRNA-9 downregulates monocyte chemotactic protein-induced protein 1 (MCPIP1) expression and induces microglia activation [86]. A study by Kumar et al. has shown that overexpression of miRNA-26a significantly decreases the production of inflammatory cytokines such as TNF-α and IL-6. In contrast, the knockdown of miRNA-26a increases the expression of these mediators [87].

Interestingly, transcriptome studies show that microglial activation is varied and context-dependent. During normal CNS function, microglia are in a so-called homeostatic state in which their transcriptomic profile reflects a surveillance activity [75, 88–92]. In sharp contrast, in neurodegeneration models, microglia express neurotoxic and neuroprotective factors; genes involved in oxidative phosphorylation; lysosome, ribosome factors, miRNAs, and responses involved in misfolded proteins, stress and neuronal injury, or death [91, 93].

4. Microglial Activation by Essential and Nonessential Metals: Cell Mechanism and Signaling Pathways

Various studies have shown that both essential and nonessential metals can accumulate in the brain and promote microglial activation; this occurs via multiple receptors and signaling pathways (Figures 3 and 4).

Figure 3

Microglia activation by essential metals. In general, it has been shown that microglial activation by excess or dysregulation of essential metals (manganese, iron, copper, zinc, and cobalt) triggers an inflammatory response. This inflammatory response results from activating PI3K, PKC, and MAPK pathways through tyrosine kinase receptors or after metal entry into the cell through metal transporters such as DMT1. This signaling triggers the nuclear translocation of transcription factor as C-Jun, HIF-1, and NF-κB, which induces gene expression such as nitric oxide synthase 2 (NOS2), TNF-α, Ccr2, IL-6, caspase 1, Cc15, and IL-1β. The inflammasome formation and the release of several inflammatory proteins in extracellular space are observed. By another hand, the deregulation of essential metals increases the production of O2.-, ROS, and NO. In the microglia is also reported the influence of essential metals on glycoprotein F4/80 expression and other receptors scarcely studied. SOS: son of sevenless; PI3K: phosphatidylinositol-4-5, bisphosphate 3 kinase; PKC: protein kinase C; PKC-δ: protein kinase delta; RAC: rac family small GTPase; JNK: c-Jun N-terminal kinase; RAS: small GTP-binding protein; Raf: serine/threonine kinase; MEK: mitogen-activated protein kinase/ERK kinase; DMT1: divalent metal transporter 1.

Figure 4

Activation of microglia by nonessential metals. It has been shown that nonessential metals (lead, aluminum, and cadmium) can activate microglial cells to an M1 phenotype; this activation does so through TLRs receptors via MyD88 and TREM2 receptors with the subsequent downstream cascade of IRAK (family of kinases) activation. Both pathways lead to the transcriptional activation of inflammatory genes and the secretion of proinflammatory interleukins such as TNF-α and IL-1β. Another signaling pathway is started by death receptors that activate apoptotic genes. In addition, exposure to these metals can increase reactive ROS and NO and trigger apoptosome formation influenced by the Bax mitochondrial release. A novel mechanism by which Al could favor the accumulation of amyloid-beta (Aβ) protein is through the activation of NF-κB and increased levels of miRNA-34a, which in turn decreases the levels of the TREM receptor that inhibits phagocytosis and thus induces the accumulation of the Aβ42 protein. The Pb deregulation in microglial cells inhibits CCR7 and MHCII receptors (TRADD (tumor necrosis factor receptor-associated DEATH domain protein); FADD (Fas-associated protein with death domain); Syk (tyrosine-protein kinase); DAP12 (transmembrane adapter well known for its role in transducing activation signals); tBID (truncated p15 BID (BH3-domain-only pro-apoptotic member)); Bax (Bcl-2 associated x-protein); and P (phosphorylation)).

4.1. Essential Metals

4.1.1. Manganese (Mn)

Manganese (Mn) is a trace element essential for human and brain development. Excess manganese is neurotoxic and has been associated with neurodegenerative disorders associated with basal ganglia dysfunction, like PD and Huntington’s disease (HD) [81, 94, 95]. Neurotoxicity induced by overexposure to Mn includes impaired mitochondrial function, metabolism of neurotransmitters, iron homeostasis, and induction of oxidative stress [96–99]. It has been shown to affect microglia and astrocytes, regulating the activation of proinflammatory responses, which contribute to its toxic effects [100]. In vitro studies have attempted to explain the molecular mechanism by which Mn has its neurotoxic effects. A report by Filipov et al. [101] describes that Mn moderately increases IL-6 and TNF-α production at cytotoxic concentrations. Moreover, Zhang et al. using a HAPI microglia cell line and exposure to 10 μM manganese chloride (MnCl₂) for 2 h reported an increased ERK and p38 activation [102]. Furthermore, Crittenden and Filipov demonstrated that p38 is critical for the Mn-induced potentiation of cytokine production to occur [103]. In the same line, a Kirkley et al. study showed that treatment with Mn in primary microglia cultures led to an increase in the proinflammatory gene expression of nitric oxide synthase 2 (Nos2), IL-1β, and caspase 1, resulting in the transition to a mixed M1/M2 phenotype and a debranched morphology [104]. Wang demonstrated that Mn activates the NLRP3-CASP1 inflammasome pathway in mice hippocampus and BV2 cells by triggering autophagy-lysosomal dysfunction. In a study carried out by Popichak et al. in which a mixed glial culture (astrocytes and microglia) was used, an MnCl₂ exposure increased the inflammatory genes Nos2, TNF-α, Cc15, IL-6, Ccr2, and IL-1β expression (see Table 1) [105]. One study by Chen et al. showed that Mn exposure induced autophagy dysfunction in vivo and in vitro and confirmed the role of leucine-rich repeat kinase 2 (LRRK2) in Mn-induced microglia neuroinflammation [106]. A report by Sarkar et al. demonstrated an increase in NLRP3 and maturation of the inflammatory cytokine IL-1β [107]. The relevant information of Harischa et al. showed that microglia exposed to Mn stimulated the release of α-Syn-containing exosomes and exhibited a pronounced amoeboid morphology resulting from the activation and formation of blebs and filopodia, like those present in other phagocytic cells. Also, the expression of Iba-1 and iNOS and the release of proinflammatory cytokines (IL-12, IL-1b, and IL-6) were significantly increased [108]. Ultimately, a study by Lin et al. reported that Mn alone did not affect amyloid-beta precursor protein (APP) and β-secretase (BACE1) expression and Aβ generation in N2a cells unless the cells were cocultured with microglia or microglia conditioned medium, pointing out that Mn treatment increased the expression level of APP, BACE1, amyloidogenic C99 fragment, and Aβ [109] (see Table 1 and Figure 3).

4.1.2. Iron (Fe)

Iron (Fe) is involved in many brain cellular processes: respiration, myelin synthesis, DNA synthesis, oxygen transport, metabolism of neurotransmitters, and many others [110]. Excessive Fe deposition has been reported in the CNS in several neurodegenerative pathologies such as AD, PD, HD, and amyotrophic lateral sclerosis (ALS) [111]. Fe is present in neurons, oligodendrocytes, astrocytes, and microglia. Within the cell, Fe mediates essential functions due to the ability to participate in electron transfer reactions, switching between two states: ferrous (II) and ferric (III) Fe. This mechanism represents a double-edged sword since the different levels of ROS are produced in these reactions allowing calcium-mediated basal synaptic transmission and the release of proinflammatory cytokines, thus creating a proinflammatory environment [112, 113].

Microglia is capable of being more efficient in Fe sequestration compared to the other brain cells. In the study by Healy et al., it is reported that ferritin is expressed in oligodendrocytes and microglia; therefore, iron accumulation loading with ferrocene affects glial morphology and number. A significant 15% increase in the number of Iba1-positive microglia was observed [114]. In another study, Bishop observed that microglia were the most efficient brain cell in accumulating Fe, followed by astrocytes and neurons [115]. On the other hand, the study by Yauger et al. demonstrated that exposure to Fe in primary microglia cultures increased ROS levels [116]. These studies documented that an increase of Fe in microglia cells led to the deregulation of iron homeostasis, either due to its excessive accumulation or modification in iron transporters. In another study by Rathore et al., the authors demonstrate that TGF-β1 and TNF-α combined with Fe reduce Fe reduce (FPN) mRNA levels and increases H-ferritin mRNA [117]. These results suggest that both cytokines promote iron uptake and retention in microglia. A study by Zhang et al. showed that exposure to Fe leads to microglial activation and enhances neurotoxicity [118]. These results demonstrate that activated microglia produce a large amount of reactive oxygen species (iROS) and a morphological alteration. The increase in mRNA and protein levels of PKC-δ, P38, ERK1/2, JNK, and NF-κB (p65) was also observed (see Table 1 and Figure 3).

4.1.3. Copper (Cu)

Copper (Cu) is a metal needed for the function of many enzymes. It functions as a cofactor and structural component of several enzymes; therefore, copper participates in many physiological pathways, including energy metabolism, antioxidative defense, and iron metabolism [119]. Alterations in brain Cu homeostasis have been implicated in AD and PD [119–123]. Although the precise mechanisms by which oligomeric Aβ species exert their toxic effects are unknown, Cu may exacerbate the toxicity of Aβ oligomers through the formation of ROS, as Aβ can mediate the reduction of Cu²⁺ to Cu⁺ [124].

A study by Hu et al. demonstrated that in microglia cells, Cu exposure increases TNF-α, NO, and iNOS levels [125]. It was found that both BAY11-7082 and SC-514, inhibitors of IκB-α phosphorylation and IKK-2, respectively, block Cu (II)-induced TNF-α or nitric oxide release in BV2 cells, suggesting a role of NF-κB in Cu (II) actions. Moreover, Cu can trigger an inflammatory process; in a study by Yu et al., it was observed that Cu (II) combined with beta-amyloid protein (Aβ) induced a phenotype of activated microglia, and the release of cytokines such as TNF-α and NO, the increase in NO, was accompanied by the expression of iNOS [126]. Kitazawa et al. found that a 24 h Cu exposure inhibits the phagocytic activation of the BV2 microglia cell line with an increase in proinflammatory cytokines such as IL-1β, TNF-α, and IL-6 release [127] (see Table 1 and Figure 3).

4.1.4. Zinc (Zn)

Zinc (Zn) is one most abundant trace elements in the brain, and it is involved in multiple functions. Zn regulates gene expression through transcription factors activity; it is responsible for the action of enzymes in metabolism and modulates various signaling pathways [128, 129]. Disruption of Zn homeostasis has been linked to neurological abnormalities, including depression, schizophrenia, AD, PD, and ALS [130]. Furthermore, released Zn by neurons under several conditions causes microglial activation and the release of proinflammatory cytokines that could cause damage to the myelin sheaths [131].

A study by Kauppinen et al. showed that Zn directly triggers microglial activation and increases NF-κB and NO production, and the glycoprotein F4/80 expression was also increased [133]. Extracellular Zn triggers microglial activation by activating NADPH oxidase, PARP-1, and NF-κB. Moreover, Higashi et al. demonstrated that Zn facilitates the expression of iNOS mRNA [134] (see Table 1 and Figure 3).

4.1.5. Cobalt (Co)

Cobalt (Co) is an element present in the earth’s crust; it is essential for mammals in the form of cobalamin (vitamin B12). The sources of Co in the air are both natural (volcano eruptions, erosion, and forest fires) and anthropogenic (burning of fossil fuels, engine emissions, and disposal of alloys) [138]. Available data on the toxic effects of Co include DNA fragmentation, caspase activation, increased ROS production, and MAPKs phosphorylation [139–142].

Excess Co is cytotoxic and neurotoxic, a study carried out by Mou et al. showed that in the N9 microglia cell line, exposure to Co induces NO production, cytokines (TNF-α and IL-6), and chemokine synthesis, in addition to the regulation of iNOS mRNA [135]. The production of Co-induced cytokines involves NF-κB as well as p38 MAPK signaling and ROS participation in microglial activation, suggesting that Co neurotoxicity should also be attributed to microglial activation that could potentiate neuronal injury through the increase of proinflammatory mediators. Another study by Kim et al. showed that CoCl₂ induces hypoxia factor 1 (HIF-1) expression, inhibits the inflammasome NLRP3, and attenuates the release of caspase 1 and IL-1β [136]. In another study by Merlo, CoCl₂ was shown to induce HIF-1 and NF-κB in rat microglial culture [137] (see Table 1 and Figure 3).

4.2. Nonessential Metals

4.2.1. Lead (Pb)

Lead (Pb) is a heavy metal widely distributed in the environment, and overexposure to this metal can affect CNS function, especially learning and memory [143, 144]. Some individuals chronically exposed to Pb have been diagnosed with learning disabilities and have difficulties in listening, speaking, reading, writing, reasoning, or mathematical abilities [145]. Disability from Pb overexposure is primarily related to neuronal injury or death [146]. Some studies have indicated that Pb can interfere with calcium signaling, suppress neurogenesis and neuronal differentiation, influence neurotransmitter release, and increase the production of Aβ [147–149]. Exposure to Pb in microglial cells results in their activation and morphological change, as well as in the induction of proinflammatory cytokines [150, 151].

In vitro, Pb exposure significantly increases microglial activation and upregulates TNF-α, IL-1β, and iNOS release [148]. A study by Liu et al. demonstrated that Pb exposure could induce significant microgliosis in the hippocampus of young mice, which is mediated most possibly through the activation of the TLR4/MyD88/NF-κB signaling cascade, augmenting the expression of inflammatory the cytokine IL-1β and TNF-α and the activation of p38-MAPK and ERK1/2 [152]. Flores-Montoya et al. showed that a low Pb concentration exposure decreases C-C chemokine receptor type 7 (CCR7) mRNA levels in microglia cells, whereas a high Pb concentration exposure diminishes MHCII levels [153]. Mu et al. reports that exposure to Pb²⁺ increases ROS and TNF-α levels and significantly impacts the expression of 16 genes related to oxidative stress and antioxidant defenses in microglia BV-2 cells [154] (see Table 2 and Figure 4).

4.2.2. Aluminum (Al)

Aluminum (Al) is a ubiquitous metal in the environment and is often used in industry to make kitchen utensils and as a pharmacological agent (antacids and antiperspirants). It is bioaccumulated after prolonged use or exposure [155]. Al exposure influences several significant reactions that result in various effects on the CNS. It affects axonal transport, neurotransmitter synthesis, synaptic transmission, protein phosphorylation/dephosphorylation, protein degradation, and inflammatory response gene expression [156]. Al³⁺ can bind strongly to metal-binding amino acids (histidine, tyrosine, arginine, etc.) or phosphorylated amino acids, resulting in protein oligomerization and inducing conformational changes that inhibit its degradation by proteases [151, 152]. By exhibiting single oxidation, Al³⁺ also binds to nucleoside phosphate groups, such as adenosine triphosphate (ATP). Therefore, it can influence energy metabolism. Al has been linked to several neurodegenerative diseases, including AD, PD, and ALS [157–160].

A study by Akinrinade et al. showed an increase in lipid peroxidation products in the brain and ROS formation after Al exposure [161]. Furthermore, an inflammatory response is also activated, increasing astrocytic and microglial activation (see Table 2 and Figure 4).

4.2.3. Cadmium (Cd)

Cadmium (Cd) is a ubiquitous industrial and environmental pollutant. It accumulates in humans and animals. The sources of human exposure to Cd are primarily anthropogenic activities such as the primary metals industry, production of batteries, consumption of contaminants, food and water, tobacco smoke, and polluted air [162]. Cd also reaches the CNS, causing neurological alterations and leading to memory and attention dysfunctions [162]. The cellular and molecular basis of Cd neurotoxicity are not precise; however, in a diversity of models of neuronal and glial cells exposed to Cd, an increase in ROS production, cell death, and disturbance of cell signaling pathways are present [162–164].

Yang et al. [165] demonstrated that in primary microglia cultures, Cd induces microglial activation through the production of ROS and the activation of transcription factors sensitive to redox, like NF-κB and AP-1, which leads to the expression of genes related to oxidative stress. Another study in vivo and in vitro by Khan et al. [166] showed that in the microglial cell line, BV-2 increased the levels of p-NF-κB. In the brain cortex and hippocampus, an augmentation of the microglia marker Iba-1 was reported, as well as an increase in TNF-α, IL-1β, NOS2, ROS, lipidic peroxidation (LPO), p-NF-κB, Bax, caspase 3, and PARP-1 (see Table 2 and Figure 4).

5. Metal Toxicity as a Risk Factor for Neurodegenerative Diseases

Neurodegenerative diseases, including AD and PD, have attracted attention in recent decades due to their high incidence worldwide. The etiology of these diseases is still unclear. However, the role of the environment as a risk factor is well documented.

Homeostasis of metal ions plays a vital role in health and neurodegenerative diseases by influencing cellular biochemical pathways. The alteration of some metal ions can lead to cytotoxic effects linked to neurodegenerative disorders such as AD and PD. Excessive concentration of nonsequestered metals can cause toxicity. In addition to altering the membrane potential, metal ions can bind to and affect protein/enzyme and nucleic acid activity, particularly in neurons. Furthermore, the leading cause of transition metals’ oxidative toxicity is ROS generation, the most penetrating oxidant in cells [99, 111, 119, 123, 130].

The exact mechanism by which metals induce toxicity is not fully understood, and each metal could likely be toxic through specific pathways. Of particular importance, oxidative stress and neurodegeneration have been reported as consequences of toxic exposures to essential and nonessential metals, along with dyshomeostasis in primary metal metabolism [167].

There is evidence of the effects of metals and their relationship with neurodegenerative diseases, as well as reports on the presence of metals in the brain of patients with AD and PD, as will be described below.

5.1. Alzheimer’s Disease (AD)

AD is the most common disease of aging and is usually considered a cognitive disorder. One of the most common neuropathological hallmarks of AD is the misfolding and aggregation of the β-amyloid peptides, senile plaques, or amyloid plaques, which mainly consist of small β-amyloid peptide (Aβ) (up to 42 or 43 amino acids long) [168, 169].

Several studies demonstrate the relationship between exposure to Mn and AD. In the study by Tong et al., a significant correlation of Mn with the Mini-Mental State Examination score and Clinical Dementia Rating Scale score was found. In addition, plasma Aβ peptides increased with elevated Mn concentrations [170]. Fe is another metal that contributes to the deposition of Aβ and the formation of neurofibrillary tangles, which promotes AD development. Brain Fe and Aβ plaques colocalization was confirmed with a quantitative susceptibility map (QSM) [171]. An analysis of AD human brains showed increased levels of Cu and Zn compared to control brains; this fact validates the hypothesis that the change in metal speciation due to the accumulation of Aβ and tau affects the brain metals homeostasis [172]. A recent meta-analysis suggested that a slight increase in serum Cu may represent a risk factor for AD [173]. In a study by Lovell et al., Zn levels are increased in senile plaque derived from patients diagnosed with AD [123]. The correlation between Co and AD or other neurodegenerative diseases is not clear. However, common mechanisms of neurotoxicity might be present. In one clinic report of a patient with arthroprosthetic cobaltism and sural nerve biopsy, neurotoxicity occurs through demyelination and axonal loss [174]. Another study by Bridges et al. demonstrated that all scanned patients had regions of significant hypometabolism and neurological toxicity from elevated systemic cobalt [175] (see Table 3).

In patients with AD, Pb levels were found to be significantly higher respect to normal subjects [176]. In the same line, increased Al levels have been traditionally linked to the pathogenesis of AD due to its accumulation in the brain [177]. Some reports have demonstrated, using histopathology, the presence of Al and amyloid plaques in different brain regions, as well as the presence of Al in glial cells [178–181]. A recent study by Exley and Clarkson confirmed that the Al content of brain tissue in AD, autism spectrum disorder, and multiple sclerosis (MS) is significantly elevated [182]. Furthermore, another study demonstrated that Al is considerably higher in MS than in non-MS [183]. Cd may also induce neurotoxicity by changing the permeability of the blood-brain barrier and interacting with other neurotoxicants, leading to Aβ aggregation and tau neurofibrillary tangle production [162]. One study using post-mortem brain tissue found that the AD brain had a higher concentration of Cd in the hippocampus and cerebral cortex [184]. Moreover, in a recent study using post-mortem brain samples from AD patients and controls, Cd concentration on the frontal cortex was lower in AD cases than in control [185]. In a meta-analysis, it was found that circulating Cd concentrations (blood, serum, or plasma) were significantly higher in AD [186] (see Table 3).

5.2. Parkinson’s Disease (PD)

PD is a complex neurodegenerative disorder with motor and nonmotor symptoms due to a spreading process of neuronal loss in the brain. A hallmark of the disease is an aggregation of the protein α-synuclein (α-Syn), which is toxic to neurons [187].

Mn is an essential mineral, but chronic exposure to high concentrations, such as it is experienced by welders, is associated with PD symptoms. On the other hand, exposure to Mn has been suggested as a PD environmental risk factor. However, manganism does not involve degeneration of the nigrostriatal dopaminergic system as in PD [189, 190]. Fe has long been described to be involved in the pathogenesis of PD. It has been observed that levels of Fe, both in its ferrous (Fe²⁺) and ferric (Fe³⁺) forms, are present in Lewy bodies (LB), as well as in many other amyloid structures [191–193]. A study by Chen et al. [194] demonstrated increased iron levels in the substantia nigra in PD patients.

Rose et al. demonstrated that Cu (II) ions accelerate the aggregation of α-Syn into fibrillar plaques, the precursors to LB [195]. However, other studies showed that in PD patients, the blood concentration of copper, ceruloplasmin, its oxidase activity, and the copper atoms per ceruloplasmin molecule were lower than in age-matched healthy individuals [196, 197]. Specifically, in PD, numerous lines of evidence indicate that aberrant Zn metabolism plays a role in the neurodegenerative cascade. The study of Kumar showed that rats treated with Zn for up to 8 weeks presented decreased locomotor activity, reflecting reduced dopamine in tyrosine hydroxylase positive cells and alteration in multiple antioxidant systems [198] (see Table 4). One meta-analysis by Du et al. suggests that reduced Zn levels in the serum and plasma are associated with an increased risk for PD [199]. Another study by Dos Santos et al. showed that patients with depression and patients with one or more of the psychotic complications of hallucination, illusion, paranoid ideation, altered dream phenomenon, and confusion exhibited significantly higher Zn concentrations in hair [200]. Another study demonstrated that plasma selenium (Se) and Fe concentrations were increased considerably, whereas Cu and Zn concentrations decreased in PD patients compared to controls [201].

Although the role of Co in PD pathogenesis has not been well documented, several reports suggested that CoCl₂, as hypoxia mimetic, can induce oxidative stress in cultured neuronal cells. It is reported that one of the mechanisms underlying CoCl₂-induced neuronal damage is associated with the production of ROS [142, 202]. In one case study by Woelber et al., a serum Co level of 116 μg/L was measured shortly after subthalamic deep brain stimulator (DBS) implantation in PD patients, and revision arthroplasty was performed using ceramic-on-polyethylene bearings [203]. After revision, the patient’s serum cobalt level fell below 1 μg/L, and the PD symptoms improved. Correlation studies between Co levels in the blood or brain tissue post-mortem are few or nonexistent. However, a recent study by Li et al. demonstrated that blood Co is associated with alterations of the blood-brain barrier and augmented oxidative stress [204] (see Table 4).

One large case-control study reported by Weisskopf et al. documents that higher accumulative exposure to Pb is associated with an increased risk of PD [205]. Also, increased Al levels have been reported in PD patients compared to controls or patients with other diseases [206, 207]. Ahmed and Santosh found that serum Al level was significantly increased in PD patients [208]. It should be mentioned that the pathogenic processes following Cd exposure result in severe cognitive impairment and are a risk factor for AD and PD [209, 210]. Individuals with AD or PD diseases present a marked loss of locus coeruleus neurons in which increased Cd levels were found [211]. Another study concluded that patients developed Parkinsonian features three months after Cd exposure [212]. These results suggest that Cd intoxication may damage the basal ganglia, resulting in Parkinsonism (see Table 4).

5.3. Microglia miRNAs Involvement in the Neurodegenerative Diseases

In recent years, increased attention has been focused on miRNAs and their relationship to neurodegenerative diseases. Many miRNAs are expressed in the brain and found as cell-free miRNAs in body fluids [213].

In microglia cells, several miRNAs contribute to the regulation of microglial polarization. Microglia-mediated mechanisms of neurotoxicity are likely to be mediated through the release of miRNAs into the extracellular environment [6, 77, 214, 215]. Dynamic mRNA regulation of neuroinflammation in astrocytes reactivity and microglia has been observed [216]. In general, miRNA-326, miRNA-155, and miRNA-27b are believed to preferentially drive a proinflammatory response, while miRNA-223, miRNA-146a, miRNA-124, and miRNA-21 are more associated with anti-inflammatory effects and let-7 family to mixed immunomodulatory regulation [216]. It is clear that specific miRNAs are involved in the development of AD, playing a role in the regulation of Aβ deposition, Tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, and autophagic dysfunction [215].

Some studies correlate the levels and regulation of specific miRNAs, the molecular mechanisms triggered in microglia, and their relationship with PD. Microglia cells have been observed to respond to IL-1β+Aβ42-peptide-induced stress by a significant NF-κB-modulated upregulation of miRNA-125b and miRNA-146a [215]. A research report by Xing demonstrated that miRNA-206 upregulation enhanced LPS-induced inflammation and Aβ release in microglia by directly targeting the 3-UTR of IGF1 [214].

Presenilin 2 (PSD2) is a membrane-associated protease that regulates proinflammatory microglial behavior. Its deficiency or dysfunction results in uncontrolled proinflammatory activation contributing to AD [6]. In this context, a study by Jayadev et al. found that PSD2 KO microglia express higher levels of the miRNA-146 target protein IL-1 receptor-associated kinase-1 and have increased NF-κB transcriptional activity [217].

In the context of neurodegenerative diseases, a study by Yao et al. demonstrated that miRNA-124 could inhibit neuroinflammation in the development of PD by regulating the MEKK3/NF-κB signaling pathways and implicated miRNA-124 as a potential therapeutic target of holding the inflammatory response in PD [218].

5.4. Metals Regulate miRNAs in Brain Cells

The cumulating evidence linking miRNAs to environmental chemicals, coupled with the unique regulatory role of miRNAs in gene expression, calls for a correlation between metal exposure and a differential miRNAs expression pattern [219, 220].

In this context, exposure to metals, such as Mn, releases extracellular miRNAs by altering the exosomal pathway in a PD model. A marked Mn-induced increase of miR-125b, a known proinflammatory miRNA, is present [221]. Moreover, Grogg and coworkers showed that miRNA-155 expression decreases upon Mn exposure [222]. In this sense, another study by Tarale et al. demonstrated that the expression of miRNA-7 and miRNA-433 was significantly reduced upon Mn exposure. The authors identified α-Syn and fibroblast growth factor 20 (FGF20) as targets of miRNA-7 and miRNA-433. The reduction in these two miRNA levels causes increases in α-Syn and FGF-20 [223].

In human primary microvascular cells (MVECs) and a mouse model of AD, it was observed that miRNA-200b-3p, miRNA-200c-3p, and miRNA-205-5p were significantly elevated within the 24 h exposure to Cu. These results support the critical regulatory role of these miRNAs in Cu-induced loss of lipoprotein receptor-related protein 1 (LRP1) [224].

Other miRNA studies in neuronal cells have focused on miRNA-146a. A study by Pogue et al. demonstrated that the NF-κB-sensitive, miRNA-146a-mediated complement factor H gene expression might contribute to inflammatory responses in Al-stressed human neuronal cells [225]. A study by Lukiw and Pogue showed that ROS-generating Al neurotoxic metal sulfates also upregulate a specific set of miRNAs that includes miRNA-9, miRNA-125b, and miRNA-128 [226].

It has also been reported that Al downregulates TREM2 expression, an effect sensitive to NF-κB and miRNA-34a. It can affect microglial phagocytic capacity and contribute to the absorption and aggregation of Aβ42, amyloidogenesis, and inflammatory degeneration of the brain [188] (see Figure 4).

6. Future Directions

As life expectancy increases, so has the incidence of degenerative diseases, with aging as a significant risk factor. Neurodegenerative diseases such as AD affect approximately 47 million people worldwide, while PD is the second most common neurodegenerative disorder.

In AD, features of microglia that relate to phagocytosis are beneficial, whereas those related to inflammation are detrimental. Microglia can be neuroprotective by degrading Aβ plaques. Depletion of microglia also results in increased plaque load, indicating that the newly recruited population has different phagocytic properties from intrinsic microglia. The phagocytic activity of microglia is attenuated by proinflammatory cytokines [227], suggesting that microglia committed to an inflammatory response may have a lower phagocytotic capacity. In studies with anti-inflammatory drugs, microglia suppression of the inflammatory response attenuates symptoms in a mouse model of AD.

In PD pathology, α-Syn is secreted to the extracellular space from neurons and detected in the extracellular biological fluids in PD patients [228]. Extracellular α-Syn directly activates microglia and triggers a proinflammatory phenotype [229, 230]. Ultimately, α-Syn-induced microglial activation promotes α-Syn phagocytosis via microglial FcγR receptor and subsequently results in a series of proinflammatory events such as NF-κB (p65) nuclear translocation leading to an elevated release of cytokines, potentiating the loss of DA neurons and chronic neurodegeneration in PD [231].

Metal ions have been implicated in these and other degenerative diseases, as several proteins undergoing amyloid aggregation have been identified as metal-binding proteins, generation of ROS, and change of proteins involved in signaling pathways that control diverse cellular processes such as apoptosis, energy metabolism, cells growth, and inflammation. Prolonged exposure to a metal mix can cause alterations in microglial function, from the loss of the ability to engulf proteins to the lack of control of the inflammatory response, causing an oxidative microenvironment that leads to neuron death and neurodegeneration.

Ultimately, reactive microglia cells are likely to play a vital role in disease progression and may lead to the identification of early biomarkers. Since these cells can drive functional changes in astrocytes, oligodendrocytes, neurons, and other brain cells [232, 233], these cells represent attractive drug targets to stop or limit disease progression. Previously, biomarkers from blood, plasma, serum, and cerebrospinal fluid (CSF) have been proposed. The most used biomarkers in AD are Aβ42, total Tau, and phospho-Tau in CSF, while α-Syn is the most promising biomarker for PD.

Several miRNAs have been identified as ideal biomarkers; these molecules are stable and easily detectable in biofluids, including plasma, serum, CSF, and urine. Cell-free miRNAs are associated with protein complexes (like the Argonaute protein family or lipoproteins) and encapsulated in vesicles, microparticles, exosomes, or apoptotic bodies). This association with proteins and vesicles protects miRNAs from being degraded by RNases in the extracellular environment [76]. Furthermore, circulating miRNAs are stable and resistant to low and high pH levels and freeze–thaw cycles, making them ideal biomarkers for pathological conditions.

In humans, it is evident that environmental factors, including toxic metals, organic pollutants, and drugs, can influence miRNA expression and function [220]. Dysregulation of specific miRNAs can contribute to microglial hyperactivation, persistent neuroinflammation, and abnormal macrophage polarization in the brain [214].

Furthermore, miRNAs may contribute to neurodegenerative diseases in response to environmental toxicant exposure via increasing oxidative stress and triggering inflammatory responses. Therefore, miRNAs play a dynamic role in many biochemical pathways in the mammalian brain, including neuroplasticity, stress responses, and cellular signaling, and have become key players in the neurodegenerative phenotype of AD and PD [76].

Emerging evidence suggests that miRNAs can ameliorate degeneration by inhibiting microglial activation in the brain. Suppression of microglial activation could be a therapeutic approach to protect neurons and, thus, treat or prevent neurodegenerative diseases [234].

7. Conclusion

As described, neurodegenerative processes in diseases like AD, PD, and others are likely to be induced by metals. Therefore, it is essential to continue the characterization of the deleterious effects of metal ion exposure in brain cells as a preliminary step to the elucidation of the cellular and molecular mechanisms that trigger the excess or deficiency of metals, as well as the alterations that these metals cause on the different cells such as astrocytes, neurons, and microglia.

Acute and chronic exposures to an endless number of metal contaminants present in water, air, soil, food, and products of daily use must be controlled. It should be taken into consideration that the possible onset of CNS pathologies may be due to contamination per se since we are exposed to these agents from the early stages of neurodevelopment to the rest of our lives. For this reason, toxicological evaluation of xenobiotics in vivo and in vitro systems is of vital importance.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

The work in the laboratory is supported by Conacyt-Mexico (255087). MIMH is supported through a Conacyt PhD Scholarship (713285).

References

O. Butovsky, M. Koronyo-Hamaoui, G. Kunis et al., “Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 31, pp. 11784–11789, 2006.
View at: Publisher Site | Google Scholar
U. K. Hanisch, “Microglia as a source and target of cytokines,” Glia, vol. 40, no. 2, pp. 140–155, 2002.
View at: Publisher Site | Google Scholar
M. S. Moehle and A. B. West, “M1 and M2 immune activation in Parkinson's Disease: Foe and ally?” Neuroscience, vol. 302, pp. 59–73, 2015.
View at: Publisher Site | Google Scholar
U. K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” Nature Neuroscience, vol. 10, no. 11, pp. 1387–1394, 2007.
View at: Publisher Site | Google Scholar
P. Taupin, “A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer’s disease,” Central Nervous System Agents in Medicinal Chemistry, vol. 10, no. 1, pp. 16–21, 2010.
View at: Publisher Site | Google Scholar
X. H. Wang and T. L. Wang, “MicroRNAs of microglia: wrestling with central nervous system disease,” Neural Regeneration Research, vol. 13, no. 12, pp. 2067–2072, 2018.
View at: Publisher Site | Google Scholar
V. M. Andrade, M. Aschner, and A. P. Marreilha Dos Santos, “Neurotoxicity of metal mixtures,” Advances in Neurobiology, vol. 18, pp. 227–265, 2017.
View at: Publisher Site | Google Scholar
P. B. Tchounwou, C. G. Yedjou, A. K. Patlolla, and D. J. Sutton, “Heavy metal toxicity and the environment,” Experientia Supplementum, vol. 101, pp. 133–164, 2012.
View at: Publisher Site | Google Scholar
T. J. Huat, J. Camats-Perna, E. A. Newcombe, N. Valmas, M. Kitazawa, and R. Medeiros, “Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation,” Journal of Molecular Biology, vol. 431, no. 9, pp. 1843–1868, 2019.
View at: Publisher Site | Google Scholar
E. J. Martinez-Finley, S. Chakraborty, S. J. B. Fretham, and M. Aschner, “Cellular transport and homeostasis of essential and nonessential metals,” Metallomics, vol. 4, no. 7, pp. 593–605, 2012.
View at: Publisher Site | Google Scholar
E. L. Que, D. W. Domaille, and C. J. Chang, “Metals in neurobiology: probing their chemistry and biology with molecular imaging,” Chemical Reviews, vol. 108, no. 5, pp. 1517–1549, 2008.
View at: Publisher Site | Google Scholar
M. L. Hegde, P. Shanmugavelu, B. Vengamma et al., “Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease,” Journal of Trace Elements in Medicine and Biology, vol. 18, no. 2, pp. 163–171, 2004.
View at: Publisher Site | Google Scholar
K. Jomova, D. Vondrakova, M. Lawson, and M. Valko, “Metals, oxidative stress and neurodegenerative disorders,” Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 91–104, 2010.
View at: Publisher Site | Google Scholar
P. Zatta, R. Lucchini, S. J. van Rensburg, and A. Taylor, “The role of metals in neurodegenerative processes: aluminum, manganese, and zinc,” Brain Research Bulletin, vol. 62, no. 1, pp. 15–28, 2003.
View at: Publisher Site | Google Scholar
P. L. McGeer and E. G. McGeer, “Inflammation and the degenerative diseases of aging,” Annals of the New York Academy of Sciences, vol. 1035, no. 1, pp. 104–116, 2004.
View at: Publisher Site | Google Scholar
H. Kettenmann, U. K. Hanisch, M. Noda, and A. Verkhratsky, “Physiology of microglia,” Physiological Reviews, vol. 91, no. 2, pp. 461–553, 2011.
View at: Publisher Site | Google Scholar
K. A. Clayton, A. A. Van Enoo, and T. Ikezu, “Alzheimer’s disease: the role of microglia in brain homeostasis and proteopathy,” Frontiers in Neuroscience, vol. 11, p. 680, 2017.
View at: Publisher Site | Google Scholar
M. T. Heneka, D. T. Golenbock, and E. Latz, “Innate immunity in Alzheimer's disease,” Nature Immunology, vol. 16, no. 3, pp. 229–236, 2015.
View at: Publisher Site | Google Scholar
K. Saijo, A. Crotti, and C. K. Glass, “Regulation of microglia activation and deactivation by nuclear receptors,” Glia, vol. 61, no. 1, pp. 104–111, 2013.
View at: Publisher Site | Google Scholar
B. L. Fiebich, C. R. A. Batista, S. W. Saliba, N. M. Yousif, and A. C. P. de Oliveira, “Role of microglia TLRs in neurodegeneration,” Frontiers in Cellular Neuroscience, vol. 12, p. 329, 2018.
View at: Publisher Site | Google Scholar
J. G. Walsh, D. A. Muruve, and C. Power, “Inflammasomes in the CNS,” Nature Reviews Neuroscience, vol. 15, no. 2, pp. 84–97, 2014.
View at: Publisher Site | Google Scholar
A. Gustin, M. Kirchmeyer, E. Koncina et al., “NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes,” PLoS One, vol. 10, no. 6, article e0130624, 2015.
View at: Publisher Site | Google Scholar
T. Masuda, R. Sankowski, O. Staszewski, and M. Prinz, “Microglia heterogeneity in the single-cell era,” Cell Reports, vol. 30, no. 5, pp. 1271–1281, 2020.
View at: Publisher Site | Google Scholar
D. Sancho and C. Reis e Sousa, “Signaling by myeloid C-type lectin receptors in immunity and homeostasis,” Annual Review of Immunology, vol. 30, no. 1, pp. 491–529, 2012.
View at: Publisher Site | Google Scholar
T. Areschoug and S. Gordon, “Scavenger receptors: role in innate immunity and microbial pathogenesis,” Cellular Microbiology, vol. 11, no. 8, pp. 1160–1169, 2009.
View at: Publisher Site | Google Scholar
I. S. Coraci, J. Husemann, J. W. Berman et al., “CD36, a Class B Scavenger Receptor, Is Expressed on Microglia in Alzheimer's Disease Brains and Can Mediate Production of Reactive Oxygen Species in Response to β-Amyloid Fibrils,” The American Journal of Pathology, vol. 160, no. 1, pp. 101–112, 2002.
View at: Publisher Site | Google Scholar
F. Granucci, F. Petralia, M. Urbano et al., “The scavenger receptor MARCO mediates cytoskeleton rearrangements in dendritic cells and microglia,” Blood, vol. 102, no. 8, pp. 2940–2947, 2003.
View at: Publisher Site | Google Scholar
A. Pocivavsek, M. P. Burns, and G. W. Rebeck, “Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase,” Glia, vol. 57, no. 4, pp. 444–453, 2009.
View at: Publisher Site | Google Scholar
G. Lemke, “Biology of the TAM receptors,” Cold Spring Harbor Perspectives in Biology, vol. 5, no. 11, article a009076, 2013.
View at: Publisher Site | Google Scholar
R. S. Scott, E. J. McMahon, S. M. Pop et al., “Phagocytosis and clearance of apoptotic cells is mediated by MER,” Nature, vol. 411, no. 6834, pp. 207–211, 2001.
View at: Publisher Site | Google Scholar
M. D. Binder, H. S. Cate, A. L. Prieto et al., “Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination,” Journal of Neuroscience, vol. 28, no. 20, pp. 5195–5206, 2008.
View at: Publisher Site | Google Scholar
L. Fourgeaud, P. G. Través, Y. Tufail et al., “TAM receptors regulate multiple features of microglial physiology,” Nature, vol. 532, no. 7598, pp. 240–244, 2016.
View at: Publisher Site | Google Scholar
C. Grommes, C. Y. D. Lee, B. L. Wilkinson et al., “Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases,” Journal of Neuroimmune Pharmacology, vol. 3, no. 2, pp. 130–140, 2008.
View at: Publisher Site | Google Scholar
J. K. Harrison, Y. Jiang, S. Chen et al., “Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 18, article 10896, 1998.
View at: Publisher Site | Google Scholar
G. K. Sheridan and K. J. Murphy, “Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage,” Open Biology, vol. 3, no. 12, article 130181, 2013.
View at: Publisher Site | Google Scholar
D. Y. Lu, C. H. Tang, W. L. Yeh et al., “SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF- kappaB-dependent pathway in microglia,” European Journal of Pharmacology, vol. 613, no. 1-3, pp. 146–154, 2009.
View at: Publisher Site | Google Scholar
A. Roy, Y. K. Fung, X. Liu, and K. Pahan, “Up-regulation of Microglial CD11b Expression by Nitric Oxide,” Journal of Biological Chemistry, vol. 281, no. 21, p. 14971, 2006.
View at: Publisher Site | Google Scholar
A. Wlodarczyk, M. Løbner, O. Cédile, and T. Owens, “Comparison of microglia and infiltrating CD11c⁺ cells as antigen presenting cells for T cell proliferation and cytokine response,” Journal of Neuroinflammation, vol. 11, no. 1, p. 57, 2014.
View at: Publisher Site | Google Scholar
A. Mildner, H. Huang, J. Radke, W. Stenzel, and J. Priller, “P2Y12receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases,” Glia, vol. 65, no. 2, pp. 375–387, 2017.
View at: Publisher Site | Google Scholar
L. Janks, C. V. R. Sharma, and T. M. Egan, “A central role for P2X7 receptors in human microglia,” Journal of Neuroinflammation, vol. 15, no. 1, p. 325, 2018.
View at: Publisher Site | Google Scholar
B. L. Fiebich, K. Biber, K. Lieb et al., “Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors,” Glia, vol. 18, no. 2, pp. 152–180, 1996.
View at: Publisher Site | Google Scholar
M. Colonna and Y. Wang, “TREM2 variants: new keys to decipher Alzheimer disease pathogenesis,” Nature Reviews Neuroscience, vol. 17, no. 4, pp. 201–207, 2016.
View at: Publisher Site | Google Scholar
R. Owens, K. Grabert, C. L. Davies et al., “Divergent neuroinflammatory regulation of microglial TREM expression and involvement of NF-κB,” Frontiers in Cellular Neuroscience, vol. 11, p. 56, 2017.
View at: Publisher Site | Google Scholar
B. Linnartz-Gerlach, M. Mathews, and H. Neumann, “Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin- like lectins,” Neuroscience, vol. 275, pp. 113–124, 2014.
View at: Publisher Site | Google Scholar
A. Bhattacherjee, E. Rodrigues, J. Jung et al., “Repression of phagocytosis by human CD33 is not conserved with mouse CD33,” Communications Biology, vol. 2, no. 1, p. 450, 2019.
View at: Publisher Site | Google Scholar
K. Shrivastava, P. Gonzalez, and L. Acarin, “The immune inhibitory complex CD200/CD200R is developmentally regulated in the mouse brain,” The Journal of Comparative Neurology, vol. 520, no. 12, pp. 2657–2675, 2012.
View at: Publisher Site | Google Scholar
S. Zhang, X. J. Wang, L. P. Tian et al., “CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease,” Journal of Neuroinflammation, vol. 8, no. 1, p. 154, 2011.
View at: Publisher Site | Google Scholar
X. Ding, J. Wang, M. Huang et al., “Loss of microglial SIRPα promotes synaptic pruning in preclinical models of neurodegeneration,” Nature Communications, vol. 12, no. 1, article 2030, 2021.
View at: Publisher Site | Google Scholar
H. Zhang, F. Li, Y. Yang, J. Chen, and X. Hu, “SIRP/CD47 signaling in neurological disorders,” Brain Research, vol. 1623, pp. 74–80, 2015.
View at: Publisher Site | Google Scholar
J. Wang, X. Ding, X. Wu et al., “SIRPα deficiency accelerates the pathologic process in models of Parkinson disease,” Glia, vol. 67, no. 12, pp. 2343–2359, 2019.
View at: Publisher Site | Google Scholar
H. Liu, R. K. Leak, and X. Hu, “Neurotransmitter receptors on microglia,” BMJ, vol. 1, no. 2, pp. 52–58, 2016.
View at: Publisher Site | Google Scholar
J. M. Pocock and H. Kettenmann, “Neurotransmitter receptors on microglia,” Trends in Neurosciences, vol. 30, no. 10, pp. 527–535, 2007.
View at: Publisher Site | Google Scholar
M. Murugan, E. A. Ling, and C. Kaur, “Glutamate receptors in microglia,” CNS & Neurological Disorders - Drug Targets, vol. 12, no. 6, pp. 773–784, 2013.
View at: Publisher Site | Google Scholar
M. Noda, H. Nakanishi, J. Nabekura, and N. Akaike, “AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia,” The Journal of Neuroscience, vol. 20, no. 1, pp. 251–258, 2000.
View at: Publisher Site | Google Scholar
Y. Hagino, Y. Kariura, Y. Manago et al., “Heterogeneity and potentiation of AMPA type of glutamate receptors in rat cultured microglia,” Glia, vol. 47, no. 1, pp. 68–77, 2004.
View at: Publisher Site | Google Scholar
A. M. Fontainhas, M. Wang, K. J. Liang et al., “Microglial morphology and dynamic behavior is regulated by ionotropic glutamatergic and GABAergic neurotransmission,” PLoS One, vol. 6, no. 1, article e15973, 2011.
View at: Publisher Site | Google Scholar
G. J. Liu, R. Nagarajah, R. B. Banati, and M. R. Bennett, “Glutamate induces directed chemotaxis of microglia,” European Journal of Neuroscience, vol. 29, no. 6, pp. 1108–1118, 2009.
View at: Publisher Site | Google Scholar
L. Acarin, B. Gonz’lez, B. Castellano, and A. J. Castro, “Microglial response to N-methyl-D-aspartate-mediated excitotoxicity in the immature rat brain,” Journal of Comparative Neurology, vol. 367, no. 3, pp. 361–374, 1996.
View at: Publisher Site | Google Scholar
M. Murugan, V. Sivakumar, J. Lu, E. A. Ling, and C. Kaur, “Expression of N-methyl D-aspartate receptor subunits in amoeboid microglia mediates production of nitric oxide via NF-κB signaling pathway and oligodendrocyte cell death in hypoxic postnatal rats,” Glia, vol. 59, no. 4, pp. 521–539, 2011.
View at: Publisher Site | Google Scholar
D. L. Taylor, L. T. Diemel, and J. M. Pocock, “Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity,” The Journal of Neuroscience, vol. 23, no. 6, pp. 2150–2160, 2003.
View at: Publisher Site | Google Scholar
D. L. Taylor, F. Jones, E. S. Kubota, and J. M. Pocock, “Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand,” Journal of Neuroscience, vol. 25, no. 11, pp. 2952–2964, 2005.
View at: Publisher Site | Google Scholar
K. R. Byrnes, B. Stoica, D. J. Loane, A. Riccio, M. I. Davis, and A. I. Faden, “Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity,” Glia, vol. 57, no. 5, pp. 550–560, 2009.
View at: Publisher Site | Google Scholar
Y. N. Zhang, J. K. Fan, L. Gu, H. M. Yang, S. Q. Zhan, and H. Zhang, “Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson’s disease,” Journal of Neuroinflammation, vol. 18, no. 1, p. 23, 2021.
View at: Publisher Site | Google Scholar
Y. Xu, M. Zhao, Y. Han, and H. Zhang, “GABAergic inhibitory interneuron deficits in Alzheimer’s disease: implications for treatment,” Frontiers in Neuroscience, vol. 14, p. 660, 2020.
View at: Publisher Site | Google Scholar
A. El-Ansary and L. Al-Ayadhi, “GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders,” J Neuroinflammation, vol. 11, no. 1, p. 189, 2014.
View at: Publisher Site | Google Scholar
T. M. Mueller and J. H. Meador-Woodruff, “Post-translational protein modifications in schizophrenia,” NPJ Schizophrenia, vol. 6, no. 1, p. 5, 2020.
View at: Publisher Site | Google Scholar
S. A. Kuhn, F. K. H. van Landeghem, R. Zacharias et al., “Microglia express GABA_B receptors to modulate interleukin release,” Molecular and Cellular Neuroscience, vol. 25, no. 2, pp. 312–322, 2004.
View at: Publisher Site | Google Scholar
J. H. Huck, D. Freyer, C. Böttcher et al., “De novo expression of dopamine D2 receptors on microglia after stroke,” Journal of Cerebral Blood Flow & Metabolism, vol. 35, no. 11, pp. 1804–1811, 2015.
View at: Publisher Site | Google Scholar
M. Pannell, M. A. Meier, F. Szulzewsky et al., “The subpopulation of microglia expressing functional muscarinic acetylcholine receptors expands in stroke and Alzheimer’s disease,” Brain Structure and Function, vol. 221, no. 2, pp. 1157–1172, 2016.
View at: Publisher Site | Google Scholar
Q. Wang, E. Oyarzabal, B. Wilson, L. Qian, and J. S. Hong, “Substance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in mice,” Clinical Science, vol. 129, no. 8, pp. 757–767, 2015.
View at: Publisher Site | Google Scholar
K. Asraf, N. Torika, A. Danon, and S. Fleisher-Berkovich, “Involvement of the bradykinin B1 receptor in microglial activation: in vitro and in vivo studies,” Frontiers in Endocrinology, vol. 8, p. 82, 2017.
View at: Publisher Site | Google Scholar
R. Franco and D. Fernandez-Suarez, “Alternatively activated microglia and macrophages in the central nervous system,” Progress in Neurobiology, vol. 131, pp. 65–86, 2015.
View at: Publisher Site | Google Scholar
A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 787–795, 2012.
View at: Publisher Site | Google Scholar
M. Colonna and O. Butovsky, “Microglia function in the central nervous system during health and neurodegeneration,” Annual Review of Immunology, vol. 35, no. 1, pp. 441–468, 2017.
View at: Publisher Site | Google Scholar
R. M. Ransohoff, “A polarizing question: do M1 and M2 microglia exist?” Nature Neuroscience, vol. 19, no. 8, pp. 987–991, 2016.
View at: Publisher Site | Google Scholar
S. Quinlan, A. Kenny, M. Medina, T. Engel, and E. M. Jimenez-Mateos, “MicroRNAs in neurodegenerative diseases,” International Review of Cell and Molecular Biology, vol. 334, pp. 309–343, 2017.
View at: Publisher Site | Google Scholar
E. D. Ponomarev, T. Veremeyko, and H. L. Weiner, “MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS,” Glia, vol. 61, no. 1, pp. 91–103, 2013.
View at: Publisher Site | Google Scholar
H. Yin, S. Song, and X. Pan, “Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection,” Journal of Inflammation, vol. 14, no. 1, p. 17, 2017.
View at: Publisher Site | Google Scholar
C. Parisi, G. Napoli, S. Amadio et al., “MicroRNA-125b regulates microglia activation and motor neuron death in ALS,” Cell Death & Differentiation, vol. 23, no. 3, pp. 531–541, 2016.
View at: Publisher Site | Google Scholar
R. Saika, H. Sakuma, D. Noto, S. Yamaguchi, T. Yamamura, and S. Miyake, “MicroRNA-101a regulates microglial morphology and inflammation,” Journal of Neuroinflammation, vol. 14, no. 1, p. 109, 2017.
View at: Publisher Site | Google Scholar
A. C. Martins Jr., P. Gubert, G. R. Villas Boas et al., “Manganese-induced neurodegenerative diseases and possible therapeutic approaches,” Expert Review of Neurotherapeutics, vol. 20, no. 11, pp. 1109–1121, 2020.
View at: Publisher Site | Google Scholar
L. Zhang, L. Y. Dong, Y. J. Li, Z. Hong, and W. S. Wei, “miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia,” Glia, vol. 60, no. 12, pp. 1888–1895, 2012.
View at: Publisher Site | Google Scholar
E. D. Ponomarev, T. Veremeyko, N. Barteneva, A. M. Krichevsky, and H. L. Weiner, “MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway,” Nature Medicine, vol. 17, no. 1, pp. 64–70, 2011.
View at: Publisher Site | Google Scholar
S. Hamzei Taj, W. Kho, M. Aswendt et al., “Dynamic modulation of microglia/macrophage polarization by miR-124 after focal cerebral ischemia,” Journal of Neuroimmune Pharmacology, vol. 11, no. 4, pp. 733–748, 2016.
View at: Publisher Site | Google Scholar
L. Li, Q. Sun, Y. Li et al., “Overexpression of SIRT1 induced by resveratrol and inhibitor of miR-204 suppresses activation and proliferation of microglia,” Journal of Molecular Neuroscience, vol. 56, no. 4, pp. 858–867, 2015.
View at: Publisher Site | Google Scholar
H. Yao, R. Ma, L. Yang et al., “miR-9 promotes microglial activation by targeting MCPIP1,” Nature Communications, vol. 5, no. 1, p. 4386, 2014.
View at: Publisher Site | Google Scholar
A. Kumar, H. S. Bhatia, A. C. P. de Oliveira, and B. L. Fiebich, “MicroRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia,” Journal of Neurochemistry, vol. 135, no. 6, pp. 1189–1202, 2015.
View at: Publisher Site | Google Scholar
O. Butovsky, M. P. Jedrychowski, C. S. Moore et al., “Identification of a unique TGF-β-dependent molecular and functional signature in microglia,” Nature Neuroscience, vol. 17, no. 1, pp. 131–143, 2014.
View at: Publisher Site | Google Scholar
D. Gosselin, V. M. Link, C. E. Romanoski et al., “Environment Drives Selection and Function of Enhancers Controlling Tissue- Specific Macrophage Identities,” Cell, vol. 159, no. 6, pp. 1327–1340, 2014.
View at: Publisher Site | Google Scholar
S. E. Hickman, N. D. Kingery, T. K. Ohsumi et al., “The microglial sensome revealed by direct RNA sequencing,” Nature Neuroscience, vol. 16, no. 12, pp. 1896–1905, 2013.
View at: Publisher Site | Google Scholar
P. D. Wes, I. R. Holtman, E. W. G. M. Boddeke, T. Möller, and B. J. L. Eggen, “Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease,” Glia, vol. 64, no. 2, pp. 197–213, 2016.
View at: Publisher Site | Google Scholar
Y. Zhang, K. Chen, S. A. Sloan et al., “An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex,” Journal of Neuroscience, vol. 34, no. 36, pp. 11929–11947, 2014.
View at: Publisher Site | Google Scholar
I. M. Chiu, E. T. A. Morimoto, H. Goodarzi et al., “A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model,” Cell Reports, vol. 4, no. 2, pp. 385–401, 2013.
View at: Publisher Site | Google Scholar
C. E. Cicero, G. Mostile, R. Vasta et al., “Metals and neurodegenerative diseases. A systematic review,” Environmental Research, vol. 159, pp. 82–94, 2017.
View at: Publisher Site | Google Scholar
R. Lucchini, D. Placidi, G. Cagna et al., “Manganese and developmental neurotoxicity,” Advances in Neurobiology, vol. 18, pp. 13–34, 2017.
View at: Publisher Site | Google Scholar
V. A. Fitsanakis, C. Au, K. M. Erikson, and M. Aschner, “The effects of manganese on glutamate, dopamine and γ-aminobutyric acid regulation,” Neurochemistry International, vol. 48, no. 6-7, pp. 426–433, 2006.
View at: Publisher Site | Google Scholar
C. Kwik-Uribe and D. R. Smith, “Temporal responses in the disruption of iron regulation by manganese,” Journal of Neuroscience Research, vol. 83, no. 8, pp. 1601–1610, 2006.
View at: Publisher Site | Google Scholar
D. Milatovic, Z. Yin, R. C. Gupta et al., “Manganese induces oxidative impairment in cultured rat astrocytes,” Toxicological Sciences, vol. 98, no. 1, pp. 198–205, 2007.
View at: Publisher Site | Google Scholar
C. Tamm, F. Sabri, and S. Ceccatelli, “Mitochondrial-mediated apoptosis in neural stem cells exposed to manganese,” Toxicological Sciences, vol. 101, no. 2, pp. 310–320, 2008.
View at: Publisher Site | Google Scholar
R. B. Tjalkens, K. A. Popichak, and K. A. Kirkley, “Inflammatory activation of microglia and astrocytes in manganese neurotoxicity,” Advances in Neurobiology, vol. 18, pp. 159–181, 2017.
View at: Publisher Site | Google Scholar
N. M. Filipov, R. F. Seegal, and D. A. Lawrence, “Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism,” Toxicological Sciences, vol. 84, no. 1, pp. 139–148, 2005.
View at: Publisher Site | Google Scholar
P. Zhang, A. Hatter, and B. Liu, “Manganese chloride stimulates rat microglia to release hydrogen peroxide,” Toxicology Letters, vol. 173, no. 2, pp. 88–100, 2007.
View at: Publisher Site | Google Scholar
P. L. Crittenden and N. M. Filipov, “Manganese-induced potentiation of _in vitro_ proinflammatory cytokine production by activated microglial cells is associated with persistent activation of p38 MAPK,” Toxicol In Vitro, vol. 22, no. 1, pp. 18–27, 2008.
View at: Publisher Site | Google Scholar
K. S. Kirkley, K. A. Popichak, M. F. Afzali, M. E. Legare, and R. B. Tjalkens, “Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity,” Journal of Neuroinflammation, vol. 14, no. 1, p. 99, 2017.
View at: Publisher Site | Google Scholar
K. A. Popichak, M. F. Afzali, K. S. Kirkley, and R. B. Tjalkens, “Glial-neuronal signaling mechanisms underlying the neuroinflammatory effects of manganese,” Journal of Neuroinflammation, vol. 15, no. 1, p. 324, 2018.
View at: Publisher Site | Google Scholar
J. Chen, P. Su, W. Luo, and J. Chen, “Role of LRRK2 in manganese-induced neuroinflammation and microglial autophagy,” Biochemical and Biophysical Research Communications, vol. 498, no. 1, pp. 171–177, 2018.
View at: Publisher Site | Google Scholar
S. Sarkar, D. Rokad, E. Malovic et al., “Manganese activates NLRP3 inflammasome signaling and propagates exosomal release of ASC in microglial cells,” Science Signaling, vol. 12, no. 563, 2019.
View at: Publisher Site | Google Scholar
D. S. Harischandra, D. Rokad, M. L. Neal et al., “Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein,” Science Signaling, vol. 12, no. 572, 2019.
View at: Publisher Site | Google Scholar
G. Lin, X. Li, X. Cheng, N. Zhao, and W. Zheng, “Manganese exposure aggravates β-Amyloid pathology by microglial activation,” Frontiers in Aging Neuroscience, vol. 12, article 556008, 2020.
View at: Publisher Site | Google Scholar
R. J. Ward, F. A. Zucca, J. H. Duyn, R. R. Crichton, and L. Zecca, “The role of iron in brain ageing and neurodegenerative disorders,” The Lancet Neurology, vol. 13, no. 10, pp. 1045–1060, 2014.
View at: Publisher Site | Google Scholar
A. Ndayisaba, C. Kaindlstorfer, and G. K. Wenning, “Iron in neurodegeneration - cause or consequence?” Frontiers in Neuroscience, vol. 13, p. 180, 2019.
View at: Publisher Site | Google Scholar
G. A. Salvador, R. M. Uranga, and N. M. Giusto, “Iron and mechanisms of neurotoxicity,” International Journal of Alzheimer's Disease, vol. 2011, article 720658, 9 pages, 2010.
View at: Publisher Site | Google Scholar
R. Williams, C. L. Buchheit, N. E. J. Berman, and S. M. LeVine, “Pathogenic implications of iron accumulation in multiple sclerosis,” Journal of Neurochemistry, vol. 120, no. 1, pp. 7–25, 2012.
View at: Publisher Site | Google Scholar
S. Healy, J. McMahon, P. Owens, and U. FitzGerald, “Significant glial alterations in response to iron loading in a novel organotypic hippocampal slice culture model,” Scientific Reports, vol. 6, no. 1, article 36410, 2016.
View at: Publisher Site | Google Scholar
G. M. Bishop, T. N. Dang, R. Dringen, and S. R. Robinson, “Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia,” Neurotoxicity Research, vol. 19, no. 3, pp. 443–451, 2011.
View at: Publisher Site | Google Scholar
Y. J. Yauger, S. Bermudez, K. E. Moritz, E. Glaser, B. Stoica, and K. R. Byrnes, “Iron accentuated reactive oxygen species release by NADPH oxidase in activated microglia contributes to oxidative stress in vitro,” Journal of Neuroinflammation, vol. 16, no. 1, p. 41, 2019.
View at: Publisher Site | Google Scholar
K. I. Rathore, A. Redensek, and S. David, “Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1,” Glia, vol. 60, no. 5, pp. 738–750, 2012.
View at: Publisher Site | Google Scholar
W. Zhang, Z. F. Yan, J. H. Gao et al., “Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration,” Molecular Neurobiology, vol. 49, no. 3, pp. 1153–1165, 2014.
View at: Publisher Site | Google Scholar
I. F. Scheiber, J. F. Mercer, and R. Dringen, “Metabolism and functions of copper in brain,” Progress in Neurobiology, vol. 116, pp. 33–57, 2014.
View at: Publisher Site | Google Scholar
D. R. Brown and H. Kozlowski, “Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases,” Dalton Transactions, vol. 13, no. 13, pp. 1907–1917, 2004.
View at: Publisher Site | Google Scholar
G. Eskici and P. H. Axelsen, “Copper and oxidative stress in the pathogenesis of Alzheimer’s disease,” Biochemistry, vol. 51, no. 32, pp. 6289–6311, 2012.
View at: Publisher Site | Google Scholar
X. Huang, C. S. Atwood, R. D. Moir, M. A. Hartshorn, R. E. Tanzi, and A. I. Bush, “Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Abeta peptides,” Journal of Biological Inorganic Chemistry, vol. 9, no. 8, pp. 954–960, 2004.
View at: Publisher Site | Google Scholar
M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell, and W. R. Markesbery, “Copper, iron and zinc in Alzheimer's disease senile plaques,” Journal of the Neurological Sciences, vol. 158, no. 1, pp. 47–52, 1998.
View at: Publisher Site | Google Scholar
B. R. Roberts, T. M. Ryan, A. I. Bush, C. L. Masters, and J. A. Duce, “The role of metallobiology and amyloid‐β peptides in Alzheimer’s disease,” Journal of Neurochemistry, vol. 120, Supplement 1, pp. 149–166, 2012.
View at: Publisher Site | Google Scholar
Z. Hu, F. Yu, P. Gong et al., “Subneurotoxic copper(II)-induced NF-κB-dependent microglial activation is associated with mitochondrial ROS,” Toxicology and Applied Pharmacology, vol. 276, no. 2, pp. 95–103, 2014.
View at: Publisher Site | Google Scholar
F. Yu, P. Gong, Z. Hu et al., “Cu(II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation,” Journal of Neuroinflammation, vol. 12, no. 1, p. 122, 2015.
View at: Publisher Site | Google Scholar
M. Kitazawa, H. W. Hsu, and R. Medeiros, “Copper exposure perturbs brain inflammatory responses and impairs clearance of amyloid-beta,” Toxicological Sciences, vol. 152, no. 1, pp. 194–204, 2016.
View at: Publisher Site | Google Scholar
S. D. Gower-Winter and C. W. Levenson, “Zinc in the central nervous system: from molecules to behavior,” Biofactors, vol. 38, no. 3, pp. 186–193, 2012.
View at: Publisher Site | Google Scholar
S. M. Hancock, D. I. Finkelstein, and P. A. Adlard, “Glia and zinc in ageing and Alzheimer’s disease: a mechanism for cognitive decline?” Frontiers in Aging Neuroscience, vol. 6, p. 137, 2014.
View at: Google Scholar
L. Mezzaroba, D. F. Alfieri, A. N. Colado Simão, and E. M. Vissoci Reiche, “The role of zinc, copper, manganese and iron in neurodegenerative diseases,” Neurotoxicology, vol. 74, pp. 230–241, 2019.
View at: Publisher Site | Google Scholar
S. Choi, D. K. Hong, B. Y. Choi, and S. W. Suh, “Zinc in the brain: friend or foe?” International Journal of Molecular Sciences, vol. 21, no. 23, p. 8941, 2020.
View at: Publisher Site | Google Scholar
D. Wang, J. Zhang, W. Jiang et al., “The role of NLRP3-CASP1 in inflammasome-mediated neuroinflammation and autophagy dysfunction in manganese-induced, hippocampal-dependent impairment of learning and memory ability,” Autophagy, vol. 13, no. 5, pp. 914–927, 2017.
View at: Publisher Site | Google Scholar
T. M. Kauppinen, Y. Higashi, S. W. Suh, C. Escartin, K. Nagasawa, and R. A. Swanson, “Zinc triggers microglial activation,” Journal of Neuroscience, vol. 28, no. 22, pp. 5827–5835, 2008.
View at: Publisher Site | Google Scholar
Y. Higashi, T. Aratake, S. Shimizu et al., “Influence of extracellular zinc on M1 microglial activation,” Scientific Reports, vol. 7, no. 1, article 43778, 2017.
View at: Publisher Site | Google Scholar
Y. H. Mou, J. Y. Yang, N. Cui et al., “Effects of cobalt chloride on nitric oxide and cytokines/chemokines production in microglia,” International Immunopharmacology, vol. 13, no. 1, pp. 120–125, 2012.
View at: Publisher Site | Google Scholar
E. H. Kim, J. H. Won, I. Hwang, and J. W. Yu, “Cobalt chloride-induced hypoxia ameliorates NLRP3-mediated caspase-1 activation in mixed glial cultures,” Immune Network, vol. 13, no. 4, pp. 141–147, 2013.
View at: Publisher Site | Google Scholar
S. Merlo, J. P. Luaces, S. F. Spampinato et al., “SIRT1 mediates melatonin’s effects on microglial activation in hypoxia: In Vitro and In Vivo Evidence,” Biomolecules, vol. 10, no. 3, p. 364, 2020.
View at: Publisher Site | Google Scholar
S. Catalani, M. C. Rizzetti, A. Padovani, and P. Apostoli, “Neurotoxicity of cobalt,” Human & Experimental Toxicology, vol. 31, no. 5, pp. 421–437, 2012.
View at: Publisher Site | Google Scholar
J. Araya, M. Maruyama, A. Inoue et al., “Inhibition of proteasome activity is involved in cobalt-induced apoptosis of human alveolar macrophages,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 283, no. 4, pp. L849–L858, 2002.
View at: Publisher Site | Google Scholar
G. Gupta, A. Gliga, J. Hedberg et al., “Cobalt nanoparticles trigger ferroptosis-like cell death (oxytosis) in neuronal cells: potential implications for neurodegenerative disease,” The FASEB Journal, vol. 34, no. 4, pp. 5262–5281, 2020.
View at: Publisher Site | Google Scholar
G. Olivieri, C. Hess, E. Savaskan et al., “Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion,” Journal of Pineal Research, vol. 31, no. 4, pp. 320–325, 2001.
View at: Publisher Site | Google Scholar
W. Zou, J. Zeng, M. Zhuo et al., “Involvement of caspase-3 and p38 mitogen-activated protein kinase in cobalt chloride-induced apoptosis in PC12 cells,” Journal of Neuroscience Research, vol. 67, no. 6, pp. 837–843, 2002.
View at: Publisher Site | Google Scholar
X. S. Luo, J. Ding, B. Xu, Y. J. Wang, H. B. Li, and S. Yu, “Incorporating bioaccessibility into human health risk assessments of heavy metals in urban park soils,” Science of The Total Environment, vol. 424, pp. 88–96, 2012.
View at: Publisher Site | Google Scholar
M. C. Senut, P. Cingolani, A. Sen et al., “Epigenetics of early-life lead exposure and effects on brain development,” Epigenomics, vol. 4, no. 6, pp. 665–674, 2012.
View at: Publisher Site | Google Scholar
D. A. Geier, J. K. Kern, and M. R. Geier, “Blood lead levels and learning disabilities: a cross-sectional study of the 2003-2004 National Health and Nutrition Examination Survey (NHANES),” International Journal of Environmental Research and Public Health, vol. 14, no. 10, article 1202, 2017.
View at: Publisher Site | Google Scholar
L. H. Mason, J. P. Harp, and D. Y. Han, “Pb neurotoxicity: neuropsychological effects of lead toxicity,” BioMed Research International, vol. 2014, Article ID 840547, 8 pages, 2014.
View at: Publisher Site | Google Scholar
M. Behl, Y. Zhang, Y. Shi, J. Cheng, Y. du, and W. Zheng, “Lead-induced accumulation of β-amyloid in the choroid plexus: Role of low density lipoprotein receptor protein-1 and protein kinase C,” Neurotoxicology, vol. 31, no. 5, pp. 524–532, 2010.
View at: Publisher Site | Google Scholar
M. C. Liu, X. Q. Liu, W. Wang et al., “Involvement of microglia activation in the lead induced long-term potentiation impairment,” PLoS One, vol. 7, no. 8, article e43924, 2012.
View at: Publisher Site | Google Scholar
C. D. Toscano, J. L. McGlothan, and T. R. Guilarte, “Lead exposure alters cyclic-AMP response element binding protein phosphorylation and binding activity in the developing rat brain,” Developmental Brain Research, vol. 145, no. 2, pp. 219–228, 2003.
View at: Publisher Site | Google Scholar
L. Strużyńska, B. Dąbrowska-Bouta, K. Koza, and G. Sulkowski, “Inflammation-like glial response in lead-exposed immature rat brain,” Toxicological Sciences, vol. 95, no. 1, pp. 156–162, 2007.
View at: Publisher Site | Google Scholar
M. G. Zurich, C. Eskes, P. Honegger, M. Bérode, and F. Monnet-Tschudi, “Maturation-dependent neurotoxicity of lead acetate in vitro: implication of glial reactions,” Journal of Neuroscience Research, vol. 70, no. 1, pp. 108–116, 2002.
View at: Publisher Site | Google Scholar
J. T. Liu, B. Y. Chen, J. Q. Zhang, F. Kuang, and L. W. Chen, “Lead exposure induced microgliosis and astrogliosis in hippocampus of young mice potentially by triggering TLR4-MyD88-NFκB signaling cascades,” Toxicology Letters, vol. 239, no. 2, pp. 97–107, 2015.
View at: Publisher Site | Google Scholar
M. G. Flores-Montoya, C. A. Bill, C. M. Vines, and C. Sobin, “Early chronic low-level lead exposure reduced C-C chemokine receptor 7 in hippocampal microglia,” Toxicology Letters, vol. 314, pp. 106–116, 2019.
View at: Publisher Site | Google Scholar
Y. Mu, J. Yu, W. Ji, L. Chen, X. Wang, and B. Yan, “Alleviation of Pb²⁺ pollution-induced oxidative stress and toxicity in microglial cells and zebrafish larvae by chicoric acid,” Ecotoxicology and Environmental Safety, vol. 180, pp. 396–402, 2019.
View at: Publisher Site | Google Scholar
M. Kawahara and M. Kato-Negishi, “Link between aluminum and the pathogenesis of Alzheimer’s disease: the integration of the aluminum and amyloid cascade hypotheses,” International Journal of Alzheimer's Disease, vol. 2011, article 276393, 17 pages, 2011.
View at: Publisher Site | Google Scholar
S. Maya, T. Prakash, K. D. Madhu, and D. Goli, “Multifaceted effects of aluminium in neurodegenerative diseases: a review,” Biomedicine & Pharmacotherapy, vol. 83, pp. 746–754, 2016.
View at: Publisher Site | Google Scholar
C. Exley and T. Vickers, “Elevated brain aluminium and early onset Alzheimer’s disease in an individual occupationally exposed to aluminium: a case report,” Journal of Medical Case Reports, vol. 8, no. 1, p. 41, 2014.
View at: Publisher Site | Google Scholar
C. A. Shaw and M. S. Petrik, “Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration,” Journal of Inorganic Biochemistry, vol. 103, no. 11, pp. 1555–1562, 2009.
View at: Publisher Site | Google Scholar
L. Tomljenovic, “Aluminum and Alzheimer’s disease: after a century of controversy, is there a plausible link?” Journal of Alzheimer's Disease, vol. 23, no. 4, pp. 567–598, 2011.
View at: Publisher Site | Google Scholar
J. R. Walton, “Aluminum involvement in the progression of Alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 35, no. 1, pp. 7–43, 2013.
View at: Publisher Site | Google Scholar
I. D. Akinrinade, A. E. Memudu, O. M. Ogundele, and O. I. Ajetunmobi, “Interplay of glia activation and oxidative stress formation in fluoride and aluminium exposure,” Pathophysiology, vol. 22, no. 1, pp. 39–48, 2015.
View at: Publisher Site | Google Scholar
R. B. Leal, D. K. Rieger, T. V. Peres, M. W. Lopes, and C. A. S. Gonçalves, “Cadmium Neurotoxicity and Its Role in Brain Disorders,” in Metal Ion in Stroke, Y. Li and J. Zhang, Eds., Springer Series in Translational Stroke Research, pp. 751–766, Springer, New York, NY, 2012.
View at: Google Scholar
J. J. V. Branca, C. Fiorillo, D. Carrino et al., “Cadmium-induced oxidative stress: focus on the central nervous system,” Antioxidants, vol. 9, no. 6, p. 492, 2020.
View at: Publisher Site | Google Scholar
L. Chen, B. Xu, L. Liu et al., “Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death,” Free Radical Biology and Medicine, vol. 50, no. 5, pp. 624–632, 2011.
View at: Publisher Site | Google Scholar
Z. Yang, S. Yang, S. Y. Qian et al., “Cadmium-induced toxicity in rat primary mid-brain neuroglia cultures: role of oxidative stress from microglia,” Toxicological Sciences, vol. 98, no. 2, pp. 488–494, 2007.
View at: Publisher Site | Google Scholar
A. Khan, M. Ikram, T. Muhammad, J. Park, and M. O. Kim, “Caffeine modulates cadmium-induced oxidative stress, neuroinflammation, and cognitive impairments by regulating Nrf-2/HO-1 in vivo and in vitro,” Journal of Clinical Medicine, vol. 8, no. 5, p. 680, 2019.
View at: Publisher Site | Google Scholar
M. Farina, D. S. Avila, J. B. T. da Rocha, and M. Aschner, “Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury,” Neurochemistry International, vol. 62, no. 5, pp. 575–594, 2013.
View at: Publisher Site | Google Scholar
C. G. Lyketsos, M. C. Carrillo, J. M. Ryan et al., “Neuropsychiatric symptoms in Alzheimer’s disease,” Alzheimer's & Dementia, vol. 7, no. 5, pp. 532–539, 2011.
View at: Publisher Site | Google Scholar
M. P. Murphy and H. LeVine 3rd, “Alzheimer’s disease and the amyloid-beta peptide,” Journal of Alzheimer's Disease, vol. 19, no. 1, pp. 311–323, 2010.
View at: Publisher Site | Google Scholar
Y. Tong, H. Yang, X. Tian et al., “High manganese, a risk for Alzheimer’s disease: high manganese induces Amyloid-β related cognitive impairment,” Journal of Alzheimer's Disease, vol. 42, no. 3, pp. 865–878, 2014.
View at: Publisher Site | Google Scholar
J. M. van Bergen, X. Li, J. Hua et al., “Colocalization of cerebral iron with amyloid beta in mild cognitive impairment,” Scientific Reports, vol. 6, no. 1, article 35514, 2016.
View at: Publisher Site | Google Scholar
F. Moynier, M. L. Borgne, E. Lahoud et al., “Copper and zinc isotopic excursions in the human brain affected by Alzheimer’s disease,” Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 12, no. 1, article e12112, 2020.
View at: Publisher Site | Google Scholar
R. Squitti, I. Simonelli, M. Ventriglia et al., “Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 38, no. 4, pp. 809–822, 2014.
View at: Publisher Site | Google Scholar
T. Ikeda, K. Takahashi, T. Kabata, D. Sakagoshi, K. Tomita, and M. Yamada, “Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement,” Muscle & Nerve, vol. 42, no. 1, pp. 140–143, 2010.
View at: Publisher Site | Google Scholar
R. L. Bridges, C. S. Cho, M. R. Beck, B. D. Gessner, and S. S. Tower, “F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 8, pp. 1961–1970, 2020.
View at: Publisher Site | Google Scholar
B. Fathabadi, M. Dehghanifiroozabadi, J. Aaseth et al., “Comparison of blood lead levels in patients with Alzheimer’s disease and healthy people,” American Journal of Alzheimer's Disease & Other Dementiasr, vol. 33, no. 8, pp. 541–547, 2018.
View at: Publisher Site | Google Scholar
D. R. Crapper, S. S. Krishnan, and A. J. Dalton, “Brain aluminum distribution in Alzheimer’s disease and experimental neurofibrillary degeneration,” Science, vol. 180, no. 4085, pp. 511–513, 1973.
View at: Publisher Site | Google Scholar
A. King, C. Troakes, M. Aizpurua et al., “Unusual neuropathological features and increased brain aluminium in a resident of Camelford, UK,” Neuropathology and Applied Neurobiology, vol. 43, no. 6, pp. 537–541, 2017.
View at: Publisher Site | Google Scholar
A. Mirza, A. King, C. Troakes, and C. Exley, “Aluminium in brain tissue in familial Alzheimer's disease,” Journal of Trace Elements in Medicine and Biology, vol. 40, pp. 30–36, 2017.
View at: Publisher Site | Google Scholar
A. Mirza, A. King, C. Troakes, and C. Exley, “The identification of aluminum in human brain tissue using Lumogallion and fluorescence microscopy,” Journal of Alzheimer's Disease, vol. 54, no. 4, pp. 1333–1338, 2016.
View at: Publisher Site | Google Scholar
M. Mold, J. Cottle, A. King, and C. Exley, “Intracellular aluminium in inflammatory and glial cells in cerebral amyloid angiopathy: a case report,” International Journal of Environmental Research and Public Health, vol. 16, no. 8, p. 1459, 2019.
View at: Publisher Site | Google Scholar
C. Exley and E. Clarkson, “Aluminium in human brain tissue from donors without neurodegenerative disease: A comparison with Alzheimer's disease, multiple sclerosis and autism,” Scientific Reports, vol. 10, no. 1, article 7770, 2020.
View at: Publisher Site | Google Scholar
C. Linhart, D. Davidson, S. Pathmanathan, T. Kamaladas, and C. Exley, “Aluminium in brain tissue in non-neurodegenerative/non-neurodevelopmental disease: a comparison with multiple sclerosis,” Exposure and Health, vol. 12, no. 4, pp. 863–868, 2020.
View at: Publisher Site | Google Scholar
N. I. Ward and J. A. Mason, “Neutron activation analysis techniques for identifying elemental status in Alzheimer’s disease,” Journal of Radioanalytical and Nuclear Chemistry, vol. 113, no. 2, pp. 515–526, 1987.
View at: Publisher Site | Google Scholar
S. T. Szabo, G. J. Harry, K. M. Hayden, D. T. Szabo, and L. Birnbaum, “Comparison of metal levels between postmortem brain and ventricular fluid in Alzheimer’s disease and nondemented elderly controls,” Toxicological Sciences, vol. 150, no. 2, pp. 292–300, 2016.
View at: Publisher Site | Google Scholar
L. Xu, W. Zhang, X. Liu, C. Zhang, P. Wang, and X. Zhao, “Circulatory levels of toxic metals (aluminum, cadmium, mercury, lead) in patients with Alzheimer’s disease: a quantitative meta-analysis and systematic review,” Journal of Alzheimer's Disease, vol. 62, no. 1, pp. 361–372, 2018.
View at: Publisher Site | Google Scholar
D. T. Dexter and P. Jenner, “Parkinson disease: from pathology to molecular disease mechanisms,” Free Radical Biology and Medicine, vol. 62, pp. 132–144, 2013.
View at: Publisher Site | Google Scholar
P. N. Alexandrov, Y. Zhao, B. M. Jones, S. Bhattacharjee, and W. J. Lukiw, “Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line,” Journal of Inorganic Biochemistry, vol. 128, pp. 267–269, 2013.
View at: Publisher Site | Google Scholar
T. R. Guilarte, “Manganese and Parkinson’s disease: a critical review and new findings,” Environmental Health Perspectives, vol. 118, no. 8, pp. 1071–1080, 2010.
View at: Publisher Site | Google Scholar
N. Kissani, Y. Naji, Y. Mebrouk, M. Chraa, and A. Ghanima, “Parkinsonism and chronic manganese exposure: pilot study with clinical, environmental and experimental evidence,” Clinical Parkinsonism & Related Disorders, vol. 3, article 100057, 2020.
View at: Publisher Site | Google Scholar
D. Berg, M. Gerlach, M. B. H. Youdim et al., “Brain iron pathways and their relevance to Parkinson’s disease,” Journal of Neurochemistry, vol. 79, no. 2, pp. 225–236, 2001.
View at: Publisher Site | Google Scholar
R. R. Crichton, D. T. Dexter, and R. J. Ward, “Brain iron metabolism and its perturbation in neurological diseases,” Journal of Neural Transmission, vol. 118, no. 3, pp. 301–314, 2011.
View at: Publisher Site | Google Scholar
M. Gerlach, M. B. H. Youdim, and P. Riederer, “Brain Iron and other Trace Metals in Neurodegenerative Diseases,” in Neurotoxic Factors in Parkinson’s Disease and Related Disorders, A. Storch and M. A. Collins, Eds., pp. 259–276, Springer, Boston, MA, 2000.
View at: Publisher Site | Google Scholar
Q. Chen, Y. Chen, Y. Zhang et al., “Iron deposition in Parkinson’s disease by quantitative susceptibility mapping,” BMC Neuroscience, vol. 20, no. 1, p. 23, 2019.
View at: Publisher Site | Google Scholar
F. Rose, M. Hodak, and J. Bernholc, “Mechanism of copper(II)-induced misfolding of Parkinson's disease protein,” Scientific Reports, vol. 1, no. 1, p. 11, 2011.
View at: Publisher Site | Google Scholar
K. M. Davies, S. Bohic, A. Carmona et al., “Copper pathology in vulnerable brain regions in Parkinson's disease,” Neurobiology of Aging, vol. 35, no. 4, pp. 858–866, 2014.
View at: Publisher Site | Google Scholar
E. Y. Ilyechova, I. V. Miliukhina, I. A. Orlov, Z. M. Muruzheva, L. V. Puchkova, and M. N. Karpenko, “A low blood copper concentration is a co-morbidity burden factor in Parkinson's disease development,” Neuroscience Research, vol. 135, pp. 54–62, 2018.
View at: Publisher Site | Google Scholar
A. Kumar, I. Ahmad, S. Shukla et al., “Effect of zinc and paraquat co-exposure on neurodegeneration: modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats,” Free Radical Research, vol. 44, no. 8, pp. 950–965, 2010.
View at: Publisher Site | Google Scholar
K. Du, M.-Y. Liu, X. Zhong, and M.-J. Wei, “Decreased circulating Zinc levels in Parkinson's disease: a meta-analysis study,” Scientific Reports, vol. 7, no. 1, p. 3902, 2017.
View at: Publisher Site | Google Scholar
A. B. Dos Santos, M. A. Bezerra, M. E. Rocha, G. E. Barreto, and K. A. Kohlmeier, “Higher zinc concentrations in hair of Parkinson’s disease are associated with psychotic complications and depression,” Journal of Neural Transmission, vol. 126, no. 10, pp. 1291–1301, 2019.
View at: Publisher Site | Google Scholar
H. W. Zhao, J. Lin, X. B. Wang et al., “Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson’s disease,” PLoS One, vol. 8, no. 12, article e83060, 2013.
View at: Publisher Site | Google Scholar
J. X. Chen, T. Zhao, and D. X. Huang, “Protective effects of edaravone against cobalt chloride-induced apoptosis in PC12 cells,” Neuroscience Bulletin, vol. 25, no. 2, pp. 67–74, 2009.
View at: Publisher Site | Google Scholar
E. Woelber, D. W. van Citters, T. Steck, G. A. Glass, and S. Tower, “Explant analysis from a patient exhibiting rapid acceleration of Parkinson disease symptoms and hypercobaltemia following metal-on-metal total hip arthroplasty: a case report,” JBJS Case Connector, vol. 6, no. 2, article e45, 2016.
View at: Publisher Site | Google Scholar
Z. Li, Z. Wang, K. Xue et al., “High concentration of blood cobalt is associated with the impairment of blood- brain barrier permeability129579,” Chemosphere, vol. 273, 2021.
View at: Publisher Site | Google Scholar
M. G. Weisskopf, J. Weuve, H. Nie et al., “Association of cumulative lead exposure with Parkinson’s disease,” Environmental Health Perspectives, vol. 118, no. 11, pp. 1609–1613, 2010.
View at: Publisher Site | Google Scholar
P. F. Good, C. W. Olanow, and D. P. Perl, “Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study,” Brain Research, vol. 593, no. 2, pp. 343–346, 1992.
View at: Publisher Site | Google Scholar
M. Yasui, T. Kihira, and K. Ota, “Calcium, magnesium and aluminum concentrations in Parkinson’s disease,” Neurotoxicology, vol. 13, no. 3, pp. 593–600, 1992.
View at: Google Scholar
S. S. S. J. Ahmed and W. Santosh, “Metallomic profiling and linkage map analysis of early Parkinson’s disease: a new insight to aluminum marker for the possible diagnosis,” PLoS One, vol. 5, no. 6, article e11252, 2010.
View at: Publisher Site | Google Scholar
K. M. Bakulski, Y. A. Seo, R. C. Hickman et al., “Heavy metals exposure and Alzheimer’s disease and related dementias,” Journal of Alzheimer's Disease, vol. 76, no. 4, pp. 1215–1242, 2020.
View at: Publisher Site | Google Scholar
B. Wang and Y. Du, “Cadmium and its neurotoxic effects,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 898034, 12 pages, 2013.
View at: Publisher Site | Google Scholar
R. Pamphlett, D. P. Bishop, S. Kum Jew, and P. A. Doble, “Age-related accumulation of toxic metals in the human locus ceruleus,” PLoS One, vol. 13, no. 9, article e0203627, 2018.
View at: Publisher Site | Google Scholar
B. Okuda, Y. Iwamoto, H. Tachibana, and M. Sugita, “Parkinsonism after acute cadmium poisoning,” Clinical Neurology and Neurosurgery, vol. 99, no. 4, pp. 263–265, 1997.
View at: Publisher Site | Google Scholar
K. S. Sheinerman and S. R. Umansky, “Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies,” Frontiers in Cellular Neuroscience, vol. 7, p. 150, 2013.
View at: Publisher Site | Google Scholar
Y. Guo, W. Hong, X. Wang et al., “MicroRNAs in microglia: how do microRNAs affect activation, inflammation, polarization of microglia and mediate the interaction between microglia and glioma?” Frontiers in Molecular Neuroscience, vol. 12, p. 125, 2019.
View at: Publisher Site | Google Scholar
X. Kou, D. Chen, and N. Chen, “The regulation of microRNAs in Alzheimer’s disease,” Frontiers in Neurology, vol. 11, p. 288, 2020.
View at: Publisher Site | Google Scholar
A. D. Gaudet, L. K. Fonken, L. R. Watkins, R. J. Nelson, and P. G. Popovich, “MicroRNAs: roles in regulating neuroinflammation,” The Neuroscientist, vol. 24, no. 3, pp. 221–245, 2018.
View at: Publisher Site | Google Scholar
S. Jayadev, A. Case, B. Alajajian, A. J. Eastman, T. Möller, and G. A. Garden, “Presenilin 2 influences miR146 level and activity in microglia,” Journal of Neurochemistry, vol. 127, no. 5, pp. 592–599, 2013.
View at: Publisher Site | Google Scholar
L. Yao, Y. Ye, H. Mao et al., “MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease,” Journal of Neuroinflammation, vol. 15, no. 1, p. 13, 2018.
View at: Publisher Site | Google Scholar
L. Hou, D. Wang, and A. Baccarelli, “Environmental chemicals and microRNAs,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 714, no. 1-2, pp. 105–112, 2011.
View at: Publisher Site | Google Scholar
D. R. Wallace, Y. M. Taalab, S. Heinze et al., “Toxic-metal-induced alteration in miRNA expression profile as a proposed mechanism for disease development,” Cells, vol. 9, no. 4, p. 901, 2020.
View at: Publisher Site | Google Scholar
D. S. Harischandra, S. Ghaisas, D. Rokad et al., “Environmental neurotoxicant manganese regulates exosome-mediated extracellular miRNAs in cell culture model of Parkinson's disease: Relevance to α-synuclein misfolding in metal neurotoxicity,” NeuroToxicology, vol. 64, pp. 267–277, 2018.
View at: Publisher Site | Google Scholar
M. W. Grogg, L. K. Braydich-Stolle, E. I. Maurer-Gardner et al., “Modulation of miRNA-155 alters manganese nanoparticle-induced inflammatory response,” Toxicology Research, vol. 5, no. 6, pp. 1733–1743, 2016.
View at: Publisher Site | Google Scholar
P. Tarale, A. P. Daiwile, S. Sivanesan et al., “Manganese exposure: Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson's disease,” Toxicol In Vitro, vol. 46, pp. 94–101, 2018.
View at: Publisher Site | Google Scholar
H. W. Hsu, C. J. Rodriguez-Ortiz, S. L. Lim et al., “Copper-induced upregulation of microRNAs directs the suppression of endothelial LRP1 in Alzheimer’s disease model,” Toxicological Sciences, vol. 170, no. 1, pp. 144–156, 2019.
View at: Publisher Site | Google Scholar
A. I. Pogue, Y. Y. Li, J. G. Cui et al., “Characterization of an NF-κB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells,” Journal of Inorganic Biochemistry, vol. 103, no. 11, pp. 1591–1595, 2009.
View at: Publisher Site | Google Scholar
W. J. Lukiw and A. I. Pogue, “Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells,” Journal of Inorganic Biochemistry, vol. 101, no. 9, pp. 1265–1269, 2007.
View at: Publisher Site | Google Scholar
J. Koenigsknecht-Talboo and G. E. Landreth, “Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines,” J Neurosci, vol. 25, no. 36, pp. 8240–8249, 2005.
View at: Publisher Site | Google Scholar
T. Tokuda, M. M. Qureshi, M. T. Ardah et al., “Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease,” Neurology, vol. 75, no. 20, pp. 1766–1770, 2010.
View at: Publisher Site | Google Scholar
S. A. Austin, A. M. Floden, E. J. Murphy, and C. K. Combs, “Alpha-synuclein expression modulates microglial activation phenotype,” Journal of Neuroscience, vol. 26, no. 41, pp. 10558–10563, 2006.
View at: Publisher Site | Google Scholar
X. Su, K. A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, and H. J. Federoff, “Synuclein activates microglia in a model of Parkinson's disease,” Neurobiology of Aging, vol. 29, no. 11, pp. 1690–1701, 2008.
View at: Publisher Site | Google Scholar
S. Cao, D. G. Standaert, and A. S. Harms, “The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia,” Journal of Neuroinflammation, vol. 9, no. 1, p. 259, 2012.
View at: Publisher Site | Google Scholar
D. A. Dionisio-Santos, J. A. Olschowka, and M. K. O'Banion, “Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease,” Journal of Neuroinflammation, vol. 16, no. 1, p. 74, 2019.
View at: Publisher Site | Google Scholar
S. A. Liddelow and B. A. Barres, “Reactive astrocytes: production, function, and therapeutic potential,” Immunity, vol. 46, no. 6, pp. 957–967, 2017.
View at: Publisher Site | Google Scholar
M. E. Lull and M. L. Block, “Microglial activation and chronic neurodegeneration,” Neurotherapeutics, vol. 7, no. 4, pp. 354–365, 2010.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 María I. Martínez-Hernández et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

220

Downloads

175

Citations